View Filing Data

TSR Awards:

Threshold Performance
(50% of Shares)

Target Performance
(100% of Shares)

Maximum Performance
(150% of Shares)

Print Document View Excel Document

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2018	Mar. 08, 2019	Jun. 30, 2018
Document And Entity Information [Abstract]
Entity Registrant Name	NN INC
Trading Symbol	NNBR
Entity Central Index Key	0000918541
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		42,104,207
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 247

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
Net sales	$ 770,657	$ 619,793	$ 584,954
Cost of sales (exclusive of depreciation and amortization shown separately below)	588,205	459,080	428,843
Selling, general and administrative expense	93,583	74,112	64,144
Acquisition related costs excluded from selling, general and administrative expense	5,871	344	0
Depreciation and amortization	71,128	52,406	50,721
Other operating (income) expense, net	6,089	351	809
Goodwill impairment	182,542	0	0
Restructuring and integration expense, net	2,127	386	5,658
Income (loss) from operations	(178,888)	33,114	34,779
Interest expense	61,243	52,085	62,870
Loss on extinguishment of debt and write-off of debt issuance costs	19,562	42,087	2,589
Derivative payments on interest rate swap	0	0	609
Derivative loss (gain) on change in interest rate swap fair value	0	(101)	2,448
Other (income) expense, net	1,341	(2,084)	(2,871)
Loss from continuing operations before benefit for income taxes and share of net income from joint venture	(261,034)	(58,873)	(30,866)
Benefit for income taxes	10,957	79,026	15,438
Share of net income (loss) from joint venture	(14,390)	5,211	5,938
Income (loss) from continuing operations	(264,467)	25,364	(9,490)
Income from discontinued operations, net of tax (Note 2)	0	137,688	16,153
Net income (loss)	(264,467)	163,052	6,663
Other comprehensive income (loss):
Change in fair value of interest rate swap	0	0	1,910
Reclassification adjustment for discontinued operations	0	(9,243)	0
Foreign currency translation gain (loss)	(13,880)	22,094	(10,623)
Other comprehensive income (loss)	(13,880)	12,851	(8,713)
Comprehensive income (loss)	$ (278,347)	$ 175,903	$ (2,050)
Basic net income (loss) per share:
Income (loss) from continuing operations per share (in usd per share)	$ (8.35)	$ 0.92	$ (0.35)
Income from discontinued operations per share (in shares)	0.00	5.02	0.60
Net income (loss) per share (in shares)	$ (8.35)	$ 5.94	$ 0.25
Weighted average shares outstanding (in shares)	31,678	27,433	27,016
Diluted net income (loss) per share:
Income (loss) from continuing operations per share (in usd per share)	$ (8.35)	$ 0.91	$ (0.35)
Income from discontinued operations per share (in usd per share)	0.00	4.96	0.60
Net income (loss) per share (in usd per share)	$ (8.35)	$ 5.87	$ 0.25
Weighted average shares outstanding (in shares)	31,678	27,755	27,016

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 17,988	$ 224,446
Accounts receivable, net	133,421	108,446
Inventories	122,615	82,617
Income tax receivable	946	43,253
Other current assets	21,901	18,518
Total current assets	296,871	477,280
Property, plant and equipment, net	361,028	259,280
Goodwill	439,452	454,612
Intangible assets, net	376,248	237,702
Investment in joint venture	20,364	39,822
Other non-current assets	7,607	6,307
Total assets	1,501,570	1,475,003
Current liabilities:
Accounts payable	65,694	52,990
Accrued salaries, wages and benefits	24,636	21,145
Current maturities of long-term debt	31,280	17,283
Other current liabilities	23,420	17,003
Total current liabilities	145,030	108,421
Deferred tax liabilities	93,482	71,564
Non-current income tax payable	3,875	5,593
Long-term debt, net of current portion	811,471	790,805
Other non-current liabilities	29,417	12,516
Total liabilities	1,083,275	988,899
Commitments and contingencies (Note 14)
Stockholders’ equity:
Common stock - $0.01 par value, authorized 45,000 shares, issued and outstanding 42,104 in 2018 and 27,572 in 2017	421	275
Additional paid-in capital	511,545	292,494
Retained (deficit) earnings	(62,046)	211,080
Accumulated other comprehensive income (loss)	(31,625)	(17,745)
Total stockholders’ equity	418,295	486,104
Total liabilities and stockholders’ equity	$ 1,501,570	$ 1,475,003

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Common Stock, par value (in USD per share)	$ 0.01	$ 0.01
Common Stock, shares authorized (in shares)	45,000,000	45,000,000
)Common Stock, shares issued (in shares)	42,104,000	27,572,000
Common Stock, shares outstanding (in shares)	42,104,000	27,572,000

Consolidated Statements of Changes in Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional paid in capital	Retained (deficit) earnings	Accumulated Other Comprehensive Income (loss)	Non- controlling interest
Beginning Balance at Dec. 31, 2015	$ 312,431	$ 269	$ 277,917	$ 56,096	$ (21,883)	$ 32
Beginning Balance, (in shares) at Dec. 31, 2015		26,849
Net income (loss)	6,663			6,663
Cash dividends declared	(7,584)			(7,584)
Share-based compensation expense	3,935	$ 0	3,935
Share-based compensation expense (in shares)		142
Shares issued for option exercises	2,832	$ 3	2,829
Shares issued for option exercises (in shares)		270
Restricted shares and performance shares forgiven for taxes and forfeited	(173)		(173)
Restricted shares and performance shares forgiven for taxes and forfeited (in shares)		(12)
Foreign currency translation loss	(10,623)				(10,623)
Change in fair value of interest rate swap	1,910				1,910
Ending Balance at Dec. 31, 2016	309,391	$ 272	284,508	55,175	(30,596)	32
Ending Balance, (in shares) at Dec. 31, 2016		27,249
Net income (loss)	163,052			163,052
Cash dividends declared	(7,887)			(7,887)
Share-based compensation expense	5,496	$ 1	5,495
Share-based compensation expense (in shares)		85
Shares issued for option exercises	3,110	$ 2	3,108
Shares issued for option exercises (in shares)		263
Sale of discontinued operations	(9,275)				(9,243)	(32)
Restricted shares and performance shares forgiven for taxes and forfeited	(617)		(617)
Restricted shares and performance shares forgiven for taxes and forfeited (in shares)		(25)
Foreign currency translation loss	22,094				22,094
Adoption of new accounting standard	740			740
Ending Balance at Dec. 31, 2017	486,104	$ 275	292,494	211,080	(17,745)	0
Ending Balance, (in shares) at Dec. 31, 2017		27,572
Net income (loss)	(264,467)			(264,467)
Cash dividends declared	(8,803)			(8,803)
Share-based compensation expense	4,384	$ 2	4,382
Share-based compensation expense (in shares)		165
Shares issued for option exercises	$ 274	$ 0	274
Shares issued for option exercises (in shares)	27	27
Restricted shares and performance shares forgiven for taxes and forfeited	$ (805)		(805)
Restricted shares and performance shares forgiven for taxes and forfeited (in shares)		(35)
Foreign currency translation loss	(13,880)				(13,880)
Adoption of new accounting standard	16			16
Shares issued	217,312	$ 144	217,168
Shares issued (in shares)		14,375
Change in estimate of performance share vesting	(1,840)		(1,968)	128
Ending Balance at Dec. 31, 2018	$ 418,295	$ 421	$ 511,545	$ (62,046)	$ (31,625)	$ 0
Ending Balance, (in shares) at Dec. 31, 2018		42,104

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net income (loss)	$ (264,467)	$ 163,052	$ 6,663
Adjustments to reconcile net income to net cash provided by (used by) operating activities:
Depreciation and amortization of continuing operations	71,128	52,406	50,721
Depreciation and amortization of discontinued operations	0	7,722	11,852
Amortization of debt issuance costs	4,845	4,296	4,168
Goodwill impairment	182,542	0	0
Other impairments	21,825	0	0
Loss on extinguishment of debt and write-off of debt issuance costs	19,562	42,087	2,589
Total derivative mark-to-market loss (gain), net of cash settlements	0	(1,483)	2,563
Share of net income from joint venture, net of cash dividends received	642	(1,284)	(2,232)
Gain on disposal of discontinued operations, net of tax and cost to sell	0	(133,665)	0
Compensation expense from issuance of share-based awards	2,416	4,730	3,935
Deferred income taxes	(20,758)	(23,195)	(15,526)
Other	1,290	100	308
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(3,543)	(11,374)	(18,505)
Inventories	(16,872)	(10,278)	4,377
Accounts payable	2,693	4,118	7,633
Income taxes receivable and payable, net	40,946	(124,389)	(217)
Other	(1,310)	(1,076)	11,023
Net cash provided by (used by) operating activities	40,939	(28,233)	69,352
Cash flows from investing activities:
Acquisition of property, plant and equipment, net of acquisitions	(64,036)	(43,722)	(43,820)
Short term investment	0	(8,000)	0
Proceeds from sale of business, net of cash sold	838	371,436	0
Cash paid to acquire businesses, net of cash received	(399,009)	(38,434)	0
Other	917	1,191	2,596
Net cash provided by (used by) investing activities	(461,290)	282,471	(41,224)
Cash flows from financing activities:
Cash paid for debt issuance or prepayment costs	(20,726)	(40,235)	(3,952)
Dividends paid	(8,826)	(7,695)	(7,584)
Proceeds from issuance of shares of common stock	217,312	0	0
Proceeds from long-term debt	311,841	322,000	44,000
Repayment of long-term debt	(290,687)	(314,313)	(55,000)
Proceeds from (repayments of) short-term debt, net	10,305	(4,211)	(456)
Other	4,126	1,382	1,489
Net cash provided by (used by) financing activities	215,093	(45,836)	(24,481)
Effect of exchange rate changes on cash flows	(1,200)	1,639	(4,329)
Net change in cash and cash equivalents	(206,458)	210,041	(682)
Cash and cash equivalents at beginning of period	224,446	14,405	15,087
Cash and cash equivalents at end of period	17,988	224,446	14,405
Supplemental schedule of non-cash operating, investing and financing activities:
Dividends accrued (reversed) for performance share units, net	(83)	192	0
Non-cash additions to property, plant and equipment	26,605	1,436	0
Restructuring charges in other current and non-current liabilities	2,071	222	3,238
Supplemental disclosures:
Cash paid for interest	56,223	52,083	59,158
Cash paid (received) for income taxes	$ (32,582)	$ 72,294	889
Cash and cash equivalents included in discontinued operations			$ 8,100

Significant Accounting Policies

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Significant Accounting Policies

Nature of Business

NN, Inc. is a global diversified industrial company that combines advanced engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision components and assemblies for the medical, aerospace and defense, electrical, automotive, and general industrial markets. As used in this Annual Report on Form 10-K, the terms “NN,” the “Company,” “we,” “our,” or “us” refer to NN, Inc., and its subsidiaries. We have 51 facilities in North America, Europe, South America, and China.

In January 2018, we implemented a new enterprise and management structure designed to accelerate growth and further balance our portfolio by aligning our strategic assets and businesses. Our businesses were reorganized into the Mobile Solutions, Power Solutions, and Life Sciences groups and are based principally on the end markets they serve. The Autocam Precision Components Group reported in our historical financial statements was renamed as Mobile Solutions. The Mobile Solutions group is focused on growth in the general industrial and automotive end markets. The Precision Engineered Products Group reported in our historical financial statements was bifurcated into two new groups – Power Solutions and Life Sciences. The Power Solutions group is focused on growth in the electrical and aerospace and defense end markets. The Life Sciences group is focused on growth in the medical end market.

Basis of Presentation

The accompanying consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”). Certain prior period amounts have been reclassified to conform to the current year’s presentation due to the 2018 adoption of the new Statement of Cash Flows guidance. Except for per share data or as otherwise indicated, all dollar amounts presented in the tables in these Notes to Consolidated Financial Statements are in thousands of U.S. dollars.

Principles of Consolidation

Our consolidated financial statements include the accounts of NN, Inc., and its wholly owned subsidiaries. We own a 49% interest in a joint venture which we account for using the equity method (see Note 10). All intercompany transactions and balances have been eliminated in consolidation.

Use of Estimates in the Preparation of Financial Statements

The preparation of financial statements in conformity with U.S. GAAP requires management to use estimates and assumptions that affect the reported amounts of certain assets and liabilities, disclosure of contingent assets and liabilities, and the reported amounts of revenues and expenses. Actual results may differ from those estimates.

Accounting Standards Recently Adopted

Revenue Recognition. On January 1, 2018, we adopted ASC Topic 606, Revenue from Contracts with Customers, (“ASC 606”). We adopted ASC 606 utilizing the modified retrospective transition method. Under this transition method, we recognized the cumulative effect of initially applying the new standard as an adjustment to the opening balance of retained earnings as of January 1, 2018, and applied the new standard beginning with the most current period presented to contracts that were not completed at the date of initial application. The adoption adjustment, which was less than $0.1 million, represents the net profit of certain contracts that were accounted for on a consignment basis under ASC Topic 605, Revenue Recognition (“ASC 605”). Under ASC 605, a sale was not recognized under these consignment contracts until the inventory was used by our customers. Under the new standard, revenue is recognized earlier because the transfer of control to our customers occurs upon shipment from our facilities as our customers have obtained the ability to direct the use of, and obtain substantially all the remaining benefits from, the asset. Comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods. See Note 16 for the required disclosures related to the impact of adopting ASC 606 and a discussion of our updated policies related to revenue recognition and accounting for costs to obtain and fulfill a customer contract.

Definition of a Business. In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-1, Business Combinations (Topic 805): Clarifying the Definition of a Business, which changes the definition of a business. The new guidance requires an entity to first evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If that threshold is met, the set of assets and activities is not a business. If the threshold is not met, the entity evaluates whether the set meets the definition of a business. The new definition requires a business to include at least one substantive process and narrows the definition of outputs by more closely aligning it with how outputs are described in the new revenue recognition guidance. The new guidance was effective for us beginning on January 1, 2018. We have applied the new definition of a business prospectively to all business combination transactions that occurred in 2018. The new guidance has no effect on our historical financial statements.

Statement of Cash Flows. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (a consensus of the Emerging Issues Task Force). This guidance provides clarification on how certain cash receipts and cash payments are presented and classified on the statement of cash flows, with focus on eight specific areas in which cash flows have, in practice, been presented inconsistently. The guidance was effective for us beginning January 1, 2018 and is required to be adopted using a retrospective approach if practicable.

The new cash flow guidance requires that cash payments for debt prepayment costs be classified as cash outflows for financing activities. We paid $31.6 million for debt prepayment costs in April 2017. These debt prepayment costs were previously classified as cash used by operating activities in 2017. Under the new guidance, these costs are reclassified to cash used by financing activities.

The new guidance also requires entities to make an accounting policy election regarding classification of distributions received from equity method investees. Existing guidance does not currently address how an entity should determine which distributions represent returns on, as opposed to returns of investment. The lack of specific guidance has resulted in diversity in practice. The two allowable approaches are the “cumulative earnings” approach and the “nature of the distribution” approach, as defined by ASU 2016-15. Upon adoption of the new guidance on January 1, 2018, we utilized the cumulative earnings approach for classifying distributions received from our joint venture investment (see Note 10). This policy election is consistent with our historical accounting.

Goodwill. In January 2017, the FASB issued ASU 2017-4, Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (“ASU 2017-4”), that eliminates the requirement to calculate the implied fair value of goodwill (i.e., Step 2 of the current goodwill impairment test) to measure a goodwill impairment charge. Instead, entities will record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (i.e., measure the charge based on the current Step 1 test). The standard is effective for us beginning with impairment tests performed on or after January 1, 2020, with early adoption permitted. We elected to early adopt the standard for our annual goodwill impairment analysis as of October 1, 2018, because the new guidance allowed us to simplify the process of calculating the impairment charge recognized as a result of our annual testing process in the current year. As a result of early adopting, we did not perform a step two analysis for the impairment testing, which may have resulted in a materially different result.

Accounting Standards Not Yet Adopted

Leases. In February 2016, the FASB issued ASU 2016-2, Leases. ASU 2016-2 creates Topic 842, Leases, (“ASC 842”) in the ASC and supersedes ASC 840, Leases. Entities that hold numerous equipment and real estate leases, in particular those with numerous operating leases, will be most affected by the new guidance. The lease accounting standard is effective for NN beginning January 1, 2019, with modified retrospective adoption required and early adoption permitted. We intend to utilize the practical expedient to recognize the cumulative-effect adoption adjustment to retained earnings as of January 1, 2019, and not adjust comparative periods. The adoption of ASC 842 is expected to impact our balance sheet by adding lease-related assets and liabilities. The loan covenants in our credit facility provide for the continuation of covenant computations in accordance with U.S. GAAP prior to changes in accounting principles. Therefore, we do not expect the adoption of ASC 842 to affect our compliance. We have performed inquiries within each of our business groups and compiled information on operating and capital leases. We are using the results of these inquiries and compiled information to evaluate the impacts of the lease accounting standard on our financial position, results of operations, and related disclosures. Upon adoption, we expect that leases with terms greater than twelve months that are currently classified as operating leases and not recorded on our balance sheet will be recognized as a right-of-use asset and lease liability. We are implementing an enterprise-wide lease accounting system and are in the process of verifying data in the system that will enable us to determine the amounts of those assets and liabilities. We have reviewed all leases and are in the process of documenting our conclusions, establishing internal controls, and determining discount rates to generate the initial accounting entries upon adoption of the standard. We expect the right-of-use asset and lease liability to be between $65.0 million and $95.0 million each.

Effects of Tax Reform in Other Comprehensive Income. In February 2018, the FASB issued guidance related to the impacts of the U.S. Tax Cuts and Jobs Act of 2017 (“Tax Act”). Under existing U.S. GAAP, the effects of changes in tax rates and laws on deferred tax balances are recorded as a component of income tax expense in the period in which the law was enacted. When deferred tax balances related to items originally recorded in accumulated other comprehensive income (“AOCI”) are adjusted, certain tax effects become stranded in AOCI. The FASB issued ASU 2018-2, Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, that permits reclassification of certain income tax effects of the Tax Act from AOCI to retained earnings. The guidance also requires certain disclosures about stranded tax effects. ASU 2018-2 is effective for us on January 1, 2019, with early adoption in any period permitted. Entities may adopt the guidance using either at the beginning of the period of adoption or retrospectively to each period in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Act is recognized. We are in the process of evaluating adoption method and the effects of this new guidance on our financial statements.

Internal-Use Software. In August 2018, the FASB issued ASU 2018-15, Intangibles - Goodwill and Other - Internal-Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (a consensus of the FASB Emerging Issues Task Force), that provides guidance on a customer’s accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement that is hosted by the vendor. Under the new guidance, customers will apply the same criteria for capitalizing implementation costs as they would for an arrangement that has a software license. ASU 2018-15 is effective for us on January 1, 2020, using either a prospective or retrospective approach and with early adoption permitted. We are in the process of evaluating the effects of this guidance on our financial statements and on cloud computing arrangements that we may enter before the required effective date.

Derivatives and Hedging. In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which provides new rules that expand the hedging strategies that qualify for hedge accounting. The new rules also allow additional time to complete hedge effectiveness testing and allow qualitative assessments subsequent to initial quantitative tests if there is supportable expectation that the hedge will remain highly effective. ASU 2017-12 is effective for us on January 1, 2019, with early adoption permitted. We do not expect the adoption of this guidance to have a material impact on our financial condition, results of operations, or cash flows.

Cash and Cash Equivalents

Cash and cash equivalents include cash and highly liquid investments with original maturities of three months or less.

Fair Value Measurements

Fair value principles prioritize valuation inputs across three broad levels. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on the assumptions used to measure assets and liabilities at fair value. An asset or liability’s classification within the various levels is determined based on the lowest level input that is significant to the fair value measurement.

Accounts Receivable and Allowance for Doubtful Accounts

Trade accounts receivable are recorded at their net realizable value. We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. The allowances are based on the number of days an individual receivable is past the invoice due date and on regular credit evaluations of our customers. In evaluating the credit worthiness of our customers, we consider numerous inputs including but not limited to the customers’ financial position, past payment history, relevant industry trends, cash flows, management capability, historical loss experience, and economic conditions and prospects. Allowances are established when customer accounts are at risk of being uncollectible. Accounts receivable are written off at the time a customer receivable is deemed uncollectible.

Inventories

Inventories are stated at the lower of cost or net realizable value. Cost is determined using standard costs, which approximates the average cost method. Our policy is to expense abnormal amounts of idle facility expense, freight, handling cost, and waste included in cost of products sold. In addition, we allocate fixed production overheads based on the normal production capacity of our facilities. Inventory valuations were developed using normalized production capacities for each of our manufacturing locations. The costs from excess capacity or under-utilization of fixed production overheads were expensed in the period incurred and are not included as a component of inventory.

Inventories also include tools, molds, and dies in progress that we are producing and will ultimately sell to our customers. These inventories are also carried at the lower of cost or net realizable value.

Property, Plant and Equipment

Property, plant and equipment are stated at cost less accumulated depreciation. Assets to be disposed of are stated at the lower of depreciated cost or fair market value less estimated selling costs. Expenditures for maintenance and repairs are charged to expense as incurred. Major renewals and betterments are capitalized. When a property item is retired, its cost and related accumulated depreciation are removed from the property accounts and any gain or loss is recorded in the Consolidated Statements of Operations and Comprehensive Income (Loss). We review the carrying values of long-lived assets for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Property, plant and equipment also includes tools, molds, and dies used in manufacturing.

Depreciation is calculated based on historical cost using the straight-line method over the estimated useful lives of the depreciable assets. Estimated useful lives for buildings generally range from 15 to 40 years. Estimated useful lives for machinery and equipment generally range from 3 to 12 years. We depreciate leasehold improvements and buildings under capital lease over the shorter of the leased asset’s useful life or the lease term.

Goodwill and Other Indefinite Lived Intangible Assets

Goodwill is tested for impairment on an annual basis in the fourth quarter and between annual tests if a triggering event occurs. The impairment analysis is performed at the reporting unit level. For the impairment test as of October 1, 2018, we elected to early adopt the new goodwill accounting standard which requires us to calculate an impairment charge based on a reporting unit’s carrying amount in excess of its fair value (i.e., step 1 of the two-step impairment test). If the carrying value of the reporting unit including goodwill is less than fair value of the reporting unit, the goodwill is not considered impaired. Under the new guidance, we no longer perform step 2 of the two-step goodwill impairment test or calculate an impairment charge using an implied fair value. Based on the results of performing the first step of the impairment test, the carrying value of certain reporting units exceed the fair value at December 31, 2018. For the year ended December 31, 2018, we recorded an impairment charge of $182.5 million to the Consolidated Statements of Operations and Comprehensive Income (Loss). See Note 8 for further discussion on goodwill.

For the year ended, December 31, 2017, we performed the two-step goodwill impairment test under accounting standards in effect at that time. Based on the results of performing the first step of the impairment test, the fair value of the reporting units exceeded the carrying value of the reporting units at December 31, 2017.

Impairment of Long-Lived Assets

Long-lived tangible and intangible assets subject to depreciation or amortization are tested for recoverability when changes in circumstances indicate the carrying value of these assets may not be recoverable. A test for recoverability is also performed when management has committed to a plan to dispose of a reporting unit or asset group. Assets to be held and used are tested for recoverability when indications of impairment are evident. Recoverability of a long-lived tangible or intangible asset is evaluated by comparing its carrying value to the future estimated undiscounted cash flows expected to be generated by the asset or asset group. If the asset is not recoverable, then the asset is considered impaired and adjusted to fair value which is then depreciated or amortized over its remaining useful life. Assets to be disposed of are recorded at the lesser of carrying value or fair value less costs of disposal.

Equity Method Investments

Each of the Company’s equity method investments is subject to a review for impairment if, and when, circumstances indicate that a decline in value below its carrying amount may have occurred. Examples of such circumstances include, but are not limited to, a significant deterioration in the earnings performance or business prospects of the investee; a significant adverse change in the regulatory, economic or technological environment of the investee; a significant adverse change in the general market condition of either the geographic area or the industry in which the investee operates; and recurring negative cash flows from operations. If management considers the decline to be other than temporary, the Company would write down the investment to its estimated fair market value.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. Provision has been made for income taxes on unremitted earnings of certain foreign subsidiaries as these earnings are not deemed to be permanently reinvested. We recognize income tax positions that meet the more likely than not threshold and accrue interest and potential penalties related to unrecognized income tax positions which are recorded as a component of the provision (benefit) for income taxes.

Revenue Recognition

We recognize revenues when control of the good or service is transferred to the customer either at a point in time or, in limited circumstances, as our services are rendered over time. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or services.

Share Based Compensation

The cost of stock options, restricted stock, and performance share units are recognized as compensation expense over the vesting periods based on the grant date fair value, net of expected forfeitures. We determine grant date fair value using the Black Scholes financial pricing model for stock options and a Monte Carlo simulation for performance share units that include a market condition for vesting because these awards are not traded in open markets. We determine grant date fair value using the closing price of our common stock on the date of grant for restricted stock and performance share units that include performance conditions for vesting. We recognize excess tax benefits in income tax expense prospectively beginning in 2017. Excess tax benefits are presented in cash flows from operating activities in the statement of cash flows prospectively beginning in 2017. Tax payments in respect of shares withheld for taxes are classified in cash flows from financing activities in the statement of cash flows retrospectively for all periods presented.

Foreign Currency Translation

Assets and liabilities of our foreign subsidiaries are translated at current exchange rates. Revenue, costs, and expenses are translated at average rates prevailing during each reporting period. Translation adjustments arising from the translation of foreign subsidiary financial statements are reported as a component of other comprehensive income and accumulated other comprehensive income within stockholders’ equity. Transactions denominated in foreign currencies, including intercompany transactions, are initially recorded at the current exchange rate at the date of the transaction. The balances are adjusted to the current exchange rate as of each balance sheet date and as of the date when the transaction is consummated. Transaction gains or losses, excluding intercompany loan transactions, are expensed as incurred in either cost of sales or selling, general and administrative expense in the Consolidated Statements of Operations and Comprehensive Income (Loss) and were immaterial to the years ended December 31, 2018, 2017 and 2016. Transaction gains or losses on intercompany loan transactions are recognized as incurred in the “Other (income) expense, net” line in the Consolidated Statements of Operations and Comprehensive Income (Loss).

Net Income Per Common Share

Basic net income per share reflects reported earnings divided by the weighted average shares outstanding. Diluted net income per share includes the effect of dilutive stock options and the respective tax benefits, unless inclusion would not be dilutive.

Business Combinations

We allocate the total purchase price of tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the business combination date, with the excess purchase price recorded as goodwill. The purchase price allocation process requires us to use significant estimates and assumptions, including fair value estimates, as of the business combination date. Although we believe the assumptions and estimates we have made are reasonable and appropriate, they are based in part on historical experience and information obtained from management of the acquired company. Our assumptions and estimates are also partially based on valuation models that incorporate projections of expected future cash flows and operating plans and are inherently uncertain. Valuations are performed by management or third-party valuation specialists under management’s supervision. In determining the fair value of assets acquired and liabilities assumed in business combinations, as appropriate, we may use one of the following recognized valuation methods: the income approach (including discounted cash flows, relief from royalty and excess earnings model), the market approach, or the replacement cost approach.

Examples of significant estimates used to value certain intangible assets acquired include but are not limited to:


•	sales volume, pricing and future cash flows of the business overall;


•	future expected cash flows from customer relationships, and other identifiable intangible assets, including future price levels, rates of increase in revenue and appropriate attrition rate;


•	the acquired company’s brand and competitive position, royalty rate quantum, as well as assumptions about the period of time the acquired brand will continue to benefit the combined company’s product portfolio; and


•	cost of capital, risk-adjusted discount rates, and income tax rates.

Different assumptions regarding projected performance and other factors associated with the acquired assets may affect the amount recorded under each type of asset and liability. The valuations of property, plant and equipment, intangible assets, goodwill and deferred income tax liabilities depend heavily on assumptions. Subsequent assessment could result in future impairment charges. We refine these estimates over a measurement period not to exceed one year to reflect new information obtained surrounding facts and circumstances existing at the acquisition date.

Discontinued Operations

12 Months Ended

Dec. 31, 2018

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

On August 17, 2017, we completed the sale of our global precision bearing components business (the “PBC Business”) and received cash proceeds at closing of $387.6 million and recorded a $0.8 million receivable, which was received in 2018. The PBC Business included all our facilities that were engaged in the production of precision steel balls, steel rollers, and metal retainers and automotive specialty products used primarily in the bearing industry. The sale of the PBC Business furthers management’s long-term strategy to build a diversified industrial business with a comprehensive geographic footprint in attractive high-growth market segments. The PBC Business represented all of the Precision Bearing Components Group reportable segment disclosed in our historical financial statements.

We recorded an after-tax gain on sale of $127.7 million, which is included in the “Income from discontinued operations, net of tax” line on the Consolidated Statements of Operations and Comprehensive Income (Loss) for the year ended December 31, 2017. The gain includes the effects of reclassifying $9.3 million in cumulative foreign currency translation gain from accumulated comprehensive income and eliminating the non-controlling interest attributable to the PBC Business as of August 17, 2017.

In accordance with ASC 205-20, Presentation of Financial Statements – Discontinued Operations, the operating results of the PBC Business are classified as discontinued operations. The presentation of discontinued operations includes revenues and expenses of the discontinued operations and gain on the disposition of the business, net of tax, as one line item on the Consolidated Statements of Operations and Comprehensive Income (Loss). Accordingly, results of the PBC Business have been excluded from continuing operations and group results for all historical periods presented in the consolidated financial statements and the accompanying notes unless otherwise stated. The Consolidated Statements of Cash Flows for the years ended December 31, 2017 and 2016, include cash flows of the PBC Business in each line item unless otherwise stated. We had no discontinued operations in the year ended December 31, 2018.

The following table summarizes the major line items included in the results of operations of the discontinued operations.



	Year Ended December 31,
	2017 ⁽¹⁾			2016
Net sales	$	168,287		$	248,534
Cost of products sold (exclusive of depreciation and amortization shown separately below)	130,555			192,994
Selling, general and administrative expense	11,818			16,992
Depreciation and amortization	7,722			11,852
Loss on disposal of assets	—			27
Restructuring and integration expense	429			4,366
Income from operations	17,763			22,303
Interest expense	(181		)	(284		)
Other income (expense), net	(84		)	503
Income from discontinued operations before gain on disposal and provision for income taxes	17,498			22,522
Provision for income taxes on discontinued operations	(7,461		)	(6,369		)
Income from discontinued operations before gain on disposal	10,037			16,153
Gain on disposal of discontinued operations	213,503			—
Provision for income taxes on gain on disposal	(85,852		)	—
Income from discontinued operations, net of tax	$	137,688		$	16,153

_________________________________


(1)	Includes the results of operations of the PBC Business from January 1, 2017 to the sale completion date of August 17, 2017.

The following table presents the significant noncash items and cash paid for capital expenditures of discontinued operations for each period presented.



	Year Ended December 31,
	2017		2016
Depreciation and amortization	$	7,722	$	11,852
Acquisition of property, plant and equipment	$	7,316	$	11,926

Acquisitions

12 Months Ended

Dec. 31, 2018

Business Combinations [Abstract]

Acquisitions

Paragon Medical, Inc.

On May 7, 2018, we acquired 100% of the stock of PMG Intermediate Holding Corporation, the parent company of Paragon Medical, Inc. (“Paragon Medical”) for a base purchase price of $375.0 million in cash, subject to certain adjustments. After working capital and other closing adjustments, the cash purchase price was approximately $390.9 million which included $13.6 million in cash acquired. During the year ended December 31, 2018, we received $1.4 million additional cash from the seller to settle working capital adjustments. For accounting purposes, Paragon Medical meets the definition of a business and has been accounted for as a business combination. Paragon Medical is a medical device manufacturer which focuses on the orthopedic, case and tray, implant, and instrument markets. This acquisition continues our strategic focus to expand our Life Sciences portfolio as well as create a balanced business by diversifying our products and finished device offerings. Operating results of Paragon Medical are reported prospectively from the date of acquisition in our Life Sciences group. We have performed an assessment of the opening balance sheet which is subject to completion of our integration procedures for accounting policies. Opening balance sheet deferred taxes have been recorded based on estimates made as of the acquisition date as well as information currently available to management. As estimates are refined and additional information is received throughout the measurement period, adjustments to opening deferred taxes may be recorded with an offsetting adjustment to goodwill. We incurred new debt in connection with the Paragon Medical acquisition and subsequently repaid the new debt in full with the proceeds from the sale of shares of our common stock as described in Note 12 and Note 15.

The following table summarizes the preliminary purchase price allocation for the Paragon Medical acquisition.



Fair value of assets acquired and liabilities assumed as of May 7, 2018	As Reported on June 30, 2018		Subsequent Adjustments to Fair Value			As Reported on December 31, 2018
Cash and cash equivalents	$	13,418	$	134		$	13,552
Accounts receivable	22,853		(721		)	22,132
Inventories	23,606		(400		)	23,206
Other current assets	937		734			1,671
Property, plant and equipment	69,322		(5,625		)	63,697
Intangible assets subject to amortization	164,200		(700		)	163,500
Other non-current assets	3,304		(129		)	3,175
Goodwill	157,421		4,399			161,820
Total assets acquired	$	455,061	$	(2,308	)	$	452,753
Current liabilities	$	16,767	$	234		$	17,001
Deferred tax liability	46,713		(2,442		)	44,271
Other non-current liabilities	620		—			620
Total liabilities assumed	$	64,100	$	(2,208	)	$	61,892
Net assets acquired	$	390,961	$	(100	)	$	390,861

We recognized measurement period adjustments during the period in which we determined the amount of the adjustment. These adjustments primarily related to estimates of the fair value of assets acquired and liabilities assumed. Measurement period adjustments were based on facts and circumstances that existed at the date of the acquisition and, if known, would have affected the measurement of the amounts recognized at the acquisition date. As a result, we adjusted the preliminary allocation of the purchase price initially recorded.

A combination of income, market, and cost approaches was used for the valuation where appropriate, depending on the asset or liability being valued. Valuation inputs in these models and analyses considered market participant assumptions. Acquired intangible assets are primarily customer relationships. As of December 31, 2018, intangible assets in connection with Paragon Medical were $155.3 million after post-acquisition amortization.

In connection with the Paragon Medical acquisition, we recorded goodwill, which represents the excess of the purchase price over the estimated fair value of tangible and intangible assets acquired, net of liabilities assumed. As of December 31, 2018, goodwill in connection with Paragon Medical was approximately $158.7 million after post-acquisition currency impacts. The goodwill is attributed primarily to Paragon Medical as a going concern, the assembled workforce, the fair value of expected cost synergies, and revenue growth expected from the ability to go to market as a combined life sciences business. The going concern element represents the ability to earn a higher return on the combined assembled collection of assets and businesses of Paragon Medical than if those assets and businesses were to be acquired and managed separately. Approximately $2.8 million of the goodwill relates to prior asset acquisitions by Paragon Medical and is expected to be deducted for tax purposes.

Property, plant and equipment acquired primarily included machinery and equipment for use in manufacturing operations. Additionally, manufacturing sites and related facilities, including leasehold improvements, were acquired. We have performed an assessment of the fair value of property, plant and equipment using both the cost approach and the market approach. The fair value assessment was supported where available by observable market data which includes consideration of obsolescence. We have performed an assessment of the fair value of intangible assets using the income approach, supported by market data, by using the relief from royalty and multi-period excess earnings methods.

We incurred approximately $5.4 million in acquisition related costs with respect to the Paragon Medical acquisition during the year ended December 31, 2018. Transaction costs were expensed as incurred and are included in the “Acquisition related costs excluded from selling, general and administrative expense” line item in the Consolidated Statements of Operations and Comprehensive Income (Loss). We expensed $12.9 million of financing costs related to the Paragon Medical acquisition during the year ended December 31, 2018, which are included in the “Loss on extinguishment of debt and write-off of debt issuance costs” line item in the Consolidated Statements of Operations and Comprehensive Income (Loss). As required by the acquisition method of accounting, acquired inventories were recorded at their estimated fair value. Beginning May 7, 2018, our consolidated results of operations include the results of Paragon Medical. Since the date of the acquisition, net sales of $117.0 million and income from operations of $8.1 million have been included in our consolidated financial statements.

The unaudited pro forma financial results shown in the table below for the years ended December 31, 2018 and 2017, combine the consolidated results of NN and Paragon Medical giving effect to the Paragon Medical acquisition as if it had been completed on January 1, 2017, the beginning of the comparable prior annual reporting period presented. The unaudited pro forma financial results do not give effect to any of our other acquisitions that occurred after January 1, 2017, and do not include any anticipated synergies or other assumed benefits of the Paragon Medical acquisition. This unaudited pro forma financial information is presented for informational purposes only and is not indicative of future operations or results had the Paragon Medical acquisition been completed as of January 1, 2017.

The unaudited pro forma financial results include certain adjustments for debt service costs and additional depreciation and amortization expense based upon the fair value step-up and estimated useful lives of Paragon Medical depreciable fixed assets and definite-life amortizable assets acquired. Adjustments for the year ended December 31, 2018, include a reduction of the prepayment penalty incurred upon the extinguishment of debt (see Note 12) as if the debt had been outstanding since January 1, 2017. The provision for income taxes has also been adjusted for all periods, based upon the foregoing adjustments to historical results. The impact of adopting ASC 606 has been included based on an adoption date of January 1, 2018.



	Year Ended December 31,
	2018			2017
Pro forma net sales	$	825,891		$	760,772
Pro forma income (loss) from continuing operations	$	(252,268	)	$	3,227
Pro forma net income (loss)	$	(252,268	)	$	140,915
Basic income (loss) from continuing operations per share	$	(7.96	)	$	0.12
Diluted income (loss) from continuing operations per share	$	(7.96	)	$	0.12

Unaudited pro forma results for the year ended December 31, 2017, include $15.0 million of inventory fair value adjustments, financing, integration, and transaction costs, net of tax, directly attributable to the acquisition which will not have an ongoing impact.

Other Acquisitions

We made other acquisitions during the years ended December 31, 2018 and 2017, with an aggregate cash purchase price of $22.0 million and $38.7 million, respectively. Amounts recorded for goodwill and intangible assets are disclosed in Note 8 and Note 9, respectively. Some of these amounts are subject to completion of our integration procedures. We incurred approximately $0.5 million and $0.3 million in acquisition related costs with respect to other acquisitions during the years ended December 31, 2018 and 2017, respectively. Transaction costs were expensed as incurred and are included in the “Acquisition related costs excluded from selling, general and administrative expense” line item in the Consolidated Statements of Operations and Comprehensive Income (Loss).

DRT Medical, LLC. On October 2, 2017, we acquired 100% of the membership interests of DRT Medical, LLC, which was subsequently named NN Life Sciences - Vandalia, LLC (“NN Vandalia”). For accounting purposes, NN Vandalia meets the definition of a business and has been accounted for as a business combination. NN Vandalia is a medical device company that supplies precision manufactured medical instruments and orthopedic implants. Operating results of NN Vandalia were reported prospectively in our Life Sciences group after the acquisition date. We finalized our valuation related to the assets acquired and liabilities assumed during 2018.

Bridgemedica, LLC. On February 22, 2018, we completed the acquisition of 100% of the assets of Bridgemedica, LLC (“Bridgemedica”). For accounting purposes, Bridgemedica meets the definition of a business and has been accounted for as a business combination. Bridgemedica is a medical device company that provides concept to supply solutions through design, development engineering and manufacturing. Operating results of Bridgemedica are reported prospectively in our Life Sciences group after the acquisition date. We have finalized our valuation related to the assets acquired and liabilities assumed.

Southern California Technical Arts, Inc. On August 9, 2018, we completed the acquisition of 100% of the capital stock of Southern California Technical Arts, Inc. (“Technical Arts”). For accounting purposes, Technical Arts meets the definition of a business and has been accounted for as a business combination. Technical Arts is an industrial machining company that manufactures tight tolerance metal components and assemblies. The acquisition of Technical Arts expands the NN presence in the aerospace and defense end market. Operating results of Technical Arts are reported prospectively in our Power Solutions group after the acquisition date. We have completed a preliminary purchase price allocation and are in the process of finalizing the fair value of assets acquired and liabilities assumed.

Segment Information

12 Months Ended

Dec. 31, 2018

Segment Reporting [Abstract]

Segment Information

We determined our reportable segments under the provisions of U.S. GAAP related to disclosures about segments of an enterprise. Management has concluded that Mobile Solutions, Power Solutions, and Life Sciences each constitutes an operating segment as each engages in business activities for which it earns revenues and incurs expenses for which separate financial information is available, and this is the level at which the Chief Operating Decision Maker (“CODM”) reviews discrete financial information for purposes of allocating resources and assessing performance. As described in Note 1, in January 2018, we implemented a new enterprise and management structure and reorganized our businesses into the Mobile Solutions, Power Solutions, and Life Sciences groups based principally on the end markets each group serves. In the first quarter of 2018, we began reporting our financial results based on these new reportable segments. Prior year amounts have been restated to conform to the current year presentation.

Mobile Solutions

Mobile Solutions is focused on growth in the general industrial and automotive end markets. We have developed an expertise in manufacturing highly complex, system critical components for fuel systems, engines and transmissions, power steering systems, and electromechanical motors on a high-volume basis. This expertise has been gained through investment in technical capabilities, processes and systems, and skilled program management and product launch capabilities.

Power Solutions

Power Solutions is focused on growth in the electrical and aerospace and defense end markets. Within this group we combine materials science expertise with advanced engineering and production capabilities to design and manufacture a broad range of high-precision metal and plastic components, assemblies, and finished devices used in applications ranging from power control to flight control and for military devices.

We manufacture a variety of products including electrical contacts, connectors, contact assemblies, and precision stampings for the electrical end market and high precision products for the aerospace and defense end markets utilizing our extensive process technologies for optical grade plastics, thermally conductive plastics, titanium, Inconel, magnesium, and electroplating.

Life Sciences

Life Sciences is focused on growth in the medical end market. Within this group we combine advanced engineering and production capabilities to design and manufacture a broad range of high-precision metal and plastic components, assemblies, and finished devices.

We manufacture a variety of components, assemblies, and instruments, such as surgical knives, bioresorbable implants, surgical staples, cases and trays, orthopedic implants and tools, laparoscopic devices, and drug delivery devices for the medical and life sciences end market.

Segment Results

The following table presents results of continuing operations for each reportable segment.



	Mobile Solutions			Power Solutions			Life Sciences		Corporate and Consolidations				Total
Year Ended December 31, 2018
Net sales	$	335,037		$	189,778		$	248,173	$	(2,331	)	(a)	$	770,657
Depreciation and amortization	$	26,217		$	14,753		$	28,091	$	2,067			$	71,128
Goodwill impairment	$	73,442		$	109,100		$	—	$	—			$	182,542
Income from operations	$	(54,103	)	$	(95,115	)	$	19,136	$	(48,806	)		$	(178,888	)
Interest expense													$	(61,243	)
Other													$	(20,903	)
Loss from continuing operations before benefit for income taxes and share of net income from joint venture													$	(261,034	)
Share of net income from joint venture	$	(14,390	)	—			—		—				$	(14,390	)
Expenditures for long-lived assets	$	36,660		$	6,459		$	14,645	$	6,272			$	64,036
Total assets	$	356,387		$	297,947		$	802,770	$	44,466		(b)	$	1,501,570
Year Ended December 31, 2017
Net sales	$	336,852		$	186,602		$	98,329	$	(1,990	)	(a)	$	619,793
Depreciation and amortization	$	24,491		$	14,657		$	12,088	$	1,170			$	52,406
Income from operations	$	34,405		$	23,440		$	13,271	$	(38,002	)		$	33,114
Interest expense													$	(52,085	)
Other													$	(39,902	)
Loss from continuing operations before benefit for income taxes and share of net income from joint venture													$	(58,873	)
Share of net income from joint venture	$	5,211		—			—		—				$	5,211
Expenditures for long-lived assets	$	24,056		$	5,443		$	—	$	6,907			$	36,406
Total assets	$	428,321		$	385,558		$	353,208	$	307,916		(b)	$	1,475,003
Year Ended December 31, 2016
Net sales	$	326,138		$	180,330		$	80,057	$	(1,571	)	(a)	$	584,954
Depreciation and amortization	$	22,189		$	15,604		$	12,501	$	427			$	50,721
Income from operations	$	29,490		$	24,060		$	9,840	$	(28,611	)		$	34,779
Interest expense													$	(62,870	)
Other													$	(2,775	)
Loss from continuing operations before benefit for income taxes and share of net income from joint venture													$	(30,866	)
Share of net income from joint venture	$	5,938		—			—		—				$	5,938
Expenditures for long-lived assets	$	23,077		$	3,125		$	2,227	$	3,465			$	31,894

_______________________________

(a) Includes eliminations of intersegment transactions which occur during the ordinary course of business.

(b) Total assets in Mobile Solutions includes $20.4 million and $39.8 million as of December 31, 2018 and 2017, respectively, related to the investment in our 49% owned joint venture (Note 10).

The following table summarizes the net sales and income (loss) from operations from the Paragon Medical and NN Vandalia acquisitions in the Life Sciences group and other acquisitions in the Life Sciences and Power Solutions groups for the years ended December 31, 2018 and 2017.



	Year Ended December 31,
	2018		2017
Net sales
Paragon Medical	$	116,998	$	—
NN Vandalia	30,668		6,682
Other	11,968		—

Income (loss) from operations
Paragon Medical	$	8,086	$	—
NN Vandalia	1,532		(458		)
Other	284		—

The following table summarizes long-lived tangible assets by geographical region.



	Property, Plant, and Equipment, Net As of December 31,
	2018		2017
United States	$	235,975	$	173,269
Europe	50,143		25,288
Asia	42,657		26,078
Mexico	7,647		7,544
S. America	24,606		27,101
All foreign countries	$	125,053	$	86,011
Total	$	361,028	$	259,280

Accounts Receivable and Sales Concentrations

12 Months Ended

Dec. 31, 2018

Receivables [Abstract]

Accounts Receivable and Sales Concentrations

Accounts receivable, net are comprised of the following amounts:



	As of December 31,
	2018		2017
Trade	$	135,260	$	110,165
Less—allowance for doubtful accounts	1,839		1,719
Accounts receivable, net	$	133,421	$	108,446

The following table presents activity in the allowance for doubtful accounts.



	Year Ended December 31,
	2018			2017			2016
Balance at beginning of year	$	1,719		$	1,069		$	1,055
Additions	754			648			153
Write-offs	(584		)	(101		)	(59		)
Currency impact	(50		)	103			(80		)
Balance at end of year	$	1,839		$	1,719		$	1,069

No customers accounted for more than 10% of our net sales for the years ended December 31, 2018 and 2017. For the year ended December 31, 2016, sales to Robert Bosch Automotive Systems (“Bosch”) amounted to $59.2 million or 10% of consolidated net sales. All revenues related to Bosch are reported in Mobile Solutions. No customers represented more than 10% of accounts receivable as of December 31, 2018 or 2017.

- Definition

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References + Details

Inventories

12 Months Ended

Dec. 31, 2018

Inventory Disclosure [Abstract]

Inventories

Inventories are comprised of the following amounts:



	As of December 31,
	2018		2017
Raw materials	$	52,930	$	37,337
Work in process	42,578		27,669
Finished goods	27,107		17,611
Inventories	$	122,615	$	82,617

Property, Plant and Equipment

12 Months Ended

Dec. 31, 2018

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

Property, plant and equipment are comprised of the following amounts:



	As of December 31,
	2018		2017
Land and buildings	$	69,455	$	54,833
Machinery and equipment	401,729		302,470
Construction in progress	35,122		14,346
Total	506,306		371,649
Less—accumulated depreciation	145,278		112,369
Property, plant and equipment, net	$	361,028	$	259,280

During the year ended December 31, 2018, we acquired $66.0 million in property, plant and equipment with the Paragon Medical, Bridgemedica, and Technical Arts acquisitions. During the year ended December 31, 2017, we acquired $14.0 million in property, plant and equipment with the NN Vandalia acquisition.

We monitor property, plant and equipment for any indicators of potential impairment. During 2018, we recognized an impairment charge of $5.2 million related to the early retirement of identified fixed assets. The impairment charge was recorded to the Other operating (income) expense, net line item on the Consolidated Statements of Operations and Comprehensive Income (Loss). The impairment charge was determined by writing the assets down to the estimated salvage value, less disposal costs. We recorded no impairment charges for the years ended December 31, 2017 and 2016.

For the years ended December 31, 2018, 2017, and 2016, we recorded depreciation expense of $38.6 million, $28.9 million, and $24.7 million, respectively.

Goodwill

12 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill

The following table shows changes in the carrying amount of goodwill for the years ended December 31, 2018, and 2017.



	Mobile Solutions			Power Solutions			Life Sciences			Total
Balance as of December 31, 2016	$	73,263		$	201,934		$	168,332		$	443,529
Currency impact	884			747			—			1,631
Goodwill acquired in acquisitions	—			—			9,452			9,452
Balance as of December 31, 2017	74,147			202,681			177,784			454,612
Currency impact and other	(705		)	(1,882		)	(3,118		)	(5,705		)
Goodwill acquired in acquisitions	—			2,657			165,288			167,945
Impairments	(73,442		)	(109,100		)	—			(182,542		)
Measurement period adjustments	—			149			4,993			5,142
Balance as of December 31, 2018	$	—		$	94,505		$	344,947		$	439,452

The following table shows the gross carrying amount of goodwill and accumulated impairment charges as of December 31, 2018 and 2017.



	December 31, 2018							December 31, 2017
	Gross Carrying Amount		Accumulated Impairment Charges			Net Book Value		Gross Carrying Amount		Accumulated Impairment Charges			Net Book Value
Mobile Solutions	$	74,147	$	(74,147	)	$	—	$	74,147	$	—		$	74,147
Power Solutions	205,405		(110,900		)	94,505		204,481		(1,800		)	202,681
Life Sciences	344,947		—			344,947		177,784		—			177,784
Total goodwill	$	624,499	$	(185,047	)	$	439,452	$	456,412	$	(1,800	)	$	454,612

Goodwill acquired in 2018 is related to the acquisitions as described in Note 3 and is derived from the value of the businesses acquired. During 2018, we recorded $161.8 million of goodwill related to the Paragon Medical acquisition, $8.0 million related to the Bridgemedica acquisition, and $2.8 million related to the Technical Arts acquisition. We have performed an assessment of the Paragon Medical opening balance sheet which is subject to completion of our integration procedures for accounting policies. For the Bridgemedica acquisition, we have finalized our valuation related to the assets acquired and liabilities assumed. For the Technical Arts acquisition, we have completed a preliminary purchase price allocation and are in the process of finalizing the fair value of assets acquired and liabilities assumed. The preliminary fair value of the businesses acquired was based on management business plans and future performance estimates which are subject to a high degree of management judgment and complexity. Actual results may differ from these projections and the differences may be material.

During 2018, as a result of the changes in our organizational and management structure, goodwill was reassigned to operating segments with goodwill assigned to Power Solutions and Life Sciences using a relative fair value allocation. For the purpose of goodwill impairment testing, the operating segments (Mobile Solutions, Power Solutions, and Life Sciences) are considered reporting units and tested on a stand-alone basis. For further information on the organizational changes, see Note 1.

During the fourth quarter 2018, our market capitalization declined to a level that was less than the net book value of our stockholders’ equity. We performed our annual goodwill impairment analysis as of October 1, 2018, and elected to early adopt ASU 2017-4. The goodwill impairment analysis required significant judgments to calculate the fair value for each of Mobile Solutions, Power Solutions, and Life Sciences, including estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term growth rate for each operating segment, and determination of weighted average cost of capital. A number of significant assumptions and estimates are involved in the application of the discounted cash flow model to forecast operating cash flows, including market growth and market share, sales volumes and prices, costs to produce, discount rate, and estimated capital needs. Management considers historical experience and all available information at the time the fair values of its reporting units are estimated. Assumptions in estimating future cash flows are subject to a high degree of judgment and complexity. Changes in assumptions and estimates may affect the fair value of goodwill and could result in impairment charges in future periods. As a result of our analysis, the Company recorded an impairment loss on goodwill of $73.4 million and $109.1 million for Mobile Solutions and Power Solutions, respectively, to the “Goodwill impairment” line on the Consolidated Statements of Operations and Comprehensive Income (Loss). In addition, goodwill in Power Solutions was reduced by $1.6 million related to adjusting deferred tax liabilities for tax deductible goodwill, which is reflected in “Currency impact and other” in the above table. No goodwill impairment loss was recorded at Life Sciences.

Power Solutions goodwill as of December 31, 2018 was $94.5 million. In conjunction with the annual goodwill impairment test during the fourth quarter of 2018, Power Solutions goodwill was impaired by $109.1 million, resulting in the carrying value of the reporting unit being equal to its fair value. If our assessment of the relevant facts and circumstances change, or if the actual performance falls short of expected results, an additional impairment charge will be required. An impairment of goodwill may also lead us to record an impairment of other intangible assets. The carrying value of finite-lived intangible assets for the Power Solutions group as of December 31, 2018, was $96.0 million.

Life Sciences has largely grown through acquisitions, with two acquisitions in 2018 plus another acquisition in late-2017. The Company is forecasting continued growth for the Life Sciences group; however, the fair value of the reporting unit exceeds the carrying value by approximately 3.7% in the most recent valuation. If our assessment of the relevant facts and circumstances change, or the actual performance falls short of expected results, impairment charges may be required. Total goodwill for the Life Sciences group as of December 31, 2018 was $344.9 million. An impairment of goodwill may also lead us to record an impairment of other intangible assets. The carrying amount of finite-lived intangible assets for the Life Sciences group as of December 31, 2018 was $244.4 million.

We completed our annual goodwill impairment review during the fourth quarters of 2017 and 2016 and concluded that there were no indicators of impairment at the reporting units with goodwill during those periods.

Intangible Assets, Net

12 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets, Net

We have identified intangible assets with finite lives primarily representing customer relationships, trademarks, and trade names. In 2018, Life Sciences added $163.5 million and $5.7 million of intangible assets related to the Paragon Medical and Bridgemedica acquisitions, respectively. In addition, in 2018, Power Solutions added $1.9 million of intangible assets related to the Technical Arts acquisition. The intangible assets acquired in 2018 primarily represent customer relationships and trademarks and trade names with a weighted average estimated useful life of the acquired intangible assets of 19 years. Refer to Note 3 for further discussion on the 2018 acquisitions.

The following table shows the nature and preliminary weighted average estimated useful lives of intangible assets acquired during the year ended December 31, 2018. Actual results may differ from these projections, and the differences may be material.



	Gross Carrying Value as of Acquisition Date		Weighted Average Estimated Useful Life in Years
Customer relationships	$	146,800	20
Trademark and trade name	14,700		29
Other	9,613		1
Total intangible assets acquired in current year	$	171,113	19

As of January 1, 2018, as a result of the changes in our organizational and management structure, intangible assets were reassigned to operating segments with intangible assets assigned to Power Solutions and Life Sciences using a relative fair value allocation. For further information on the organizational changes, see Note 1.

The following table shows changes in the carrying amount of intangible assets, net.



	Mobile Solutions			Power Solutions			Life Sciences			Total
Balance as of December 31, 2016	$	42,928		$	115,928		$	95,407		$	254,263
Amortization	(3,481		)	(10,898		)	(9,081		)	(23,460		)
Currency impacts	(1		)	—			—			(1		)
Intangible assets acquired in acquisition	—			—			6,900			6,900
Balance as of December 31, 2017	$	39,446		$	105,030		$	93,226		$	237,702
Amortization	(3,540		)	(10,939		)	(18,074		)	(32,553		)
Currency impacts	(14		)	—			—			(14		)
Intangible assets acquired in acquisitions	—			1,900			169,213			171,113
Measurement period adjustments	—			—			—			—
Balance as of December 31, 2018	$	35,892		$	95,991		$	244,365		$	376,248

The following table shows the cost and accumulated amortization of our intangible assets as of December 31, 2018 and 2017.



		December 31, 2018							December 31, 2017
	Estimated Useful Life in Years	Gross Carrying Value as of Acquisition Date		Accumulated Amortization			Net Carrying Value		Gross Carrying Value as of Acquisition Date		Accumulated Amortization			Net Carrying Value
Customer relationships	12 - 20	$	428,830	$	(75,581	)	$	353,249	$	282,030	$	(52,408	)	$	229,622
Trademark and trade name	8 - 30	25,100		(4,085		)	21,015		10,460		(2,703		)	7,757
Other	1 - 5	10,641		(8,657		)	1,984		8,740		(8,417		)	323
Total identified intangible assets		$	464,571	$	(88,323	)	$	376,248	$	301,230	$	(63,528	)	$	237,702

Intangible assets that become fully amortized are removed from the accounts and are no longer represented in the gross carrying value or accumulated amortization.

The following table summarizes estimated future amortization expense for the next five years and thereafter.




Year Ending December 31,
2019	$	47,009
2020	45,357
2021	41,415
2022	38,464
2023	36,625
Thereafter	167,378
Total	$	376,248

Intangible assets are tested for impairment when changes in circumstances indicate the carrying value of those assets may not be recoverable. As of December 31, 2018 and 2017, there were no indications of impairment.

Investment in Joint Venture

12 Months Ended

Dec. 31, 2018

Equity Method Investments and Joint Ventures [Abstract]

Investment in Joint Venture

We own a 49% investment in Wuxi Weifu Autocam Precision Machinery Company, Ltd. (the “JV”), a joint venture located in Wuxi, China. The JV is jointly controlled and managed, and we account for it under the equity method.

The following table summarizes activity related to our investment in the JV.



Balance as of December 31, 2017	$	39,822
Share of earnings	2,543
Dividends declared and paid by joint venture	(2,842		)
Accretion of basis difference from purchase accounting	(343		)
Foreign currency translation loss	(2,227		)
Impairment	(16,589		)
Balance as of December 31, 2018	$	20,364

During the year ended December 31, 2018, the fair value of the JV was assessed as a result of changing market conditions. Based on the results of the assessment, we determined the carrying amount of the investment exceed its estimated fair market value, and we believe this condition is other than temporary, as defined by the accounting standards. As a result, we recorded an impairment charge of $16.6 million against our investment in the JV. This charge is included in the line item “Share of net income from joint venture” line on the Consolidated Statements of Operations and Comprehensive Income (Loss). The fair value assessment was most significantly affected by growth rates. It is reasonably possible that material deviation of future performance from the estimates used in the valuation could result in further impairment to our investment in the JV.

The following tables show selected financial data of the JV.



	Year Ended December 31,
	2018		2017		2016
Net sales	$	69,901	$	74,805	$	65,756
Cost of sales	57,596		57,514		44,530
Income from operations	6,853		13,659		16,268
Net income	4,646		11,442		13,702

We recognized sales to the JV of $0.3 million, $0.2 million, and $0.1 million for the years ended December 31, 2018, 2017, and 2016, respectively. Amounts due to us from the JV were $0.1 million, $0.1 million, and $0.1 million as of December 31, 2018, 2017, and 2016, respectively.

Income Taxes

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Income Taxes

On December 22, 2017, the U.S. government enacted comprehensive tax legislation. The Tax Act reduced the U.S. federal corporate income tax rate from 35% to 21%, required companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred, and created new taxes on certain foreign sourced earnings. As a result of the Tax Act, we recognized a $51.8 million net tax benefit in 2017, which included the estimate of transition tax and the remeasurement of our domestic deferred taxes from 35% to 21%.

As of December 31, 2018, the Company considers the accounting under Staff Accounting Bulletin No. 118 for the impacts of the Tax Act to be complete. In preparing the amounts as of December 31, 2018, the Company considered notices, revenue procedures, and proposed regulations issued by the Internal Revenue Service and authoritative accounting guidance to date. In 2018, the Company recognized an adjustment to the 2017 net tax benefit which decreased earnings by $0.8 million. This adjustment was primarily related to the one-time transition tax on deferred foreign income, change in valuation of deferred tax assets associated with tax law changes, and remeasurement of deferred taxes.

On February 5, 2019, the Department of the Treasury and Internal Revenue Service published final regulations pertaining to the transition tax enacted as part of the Tax Act. The Company is still in the process of analyzing the impact of these regulations, which were issued subsequent to the balance sheet date of December 31, 2018. Based upon a preliminary analysis of the final regulations, we anticipate an increase to tax expense of approximately $6.0 million for the year ended December 31, 2019. The Company's analysis is on-going and the adjustment will be recorded in 2019 during the period of enactment of the regulations.

Loss from continuing operations before benefit for income taxes was as follows:



	Year Ended December 31,
	2018			2017			2016
Loss from continuing operations before benefit for income taxes and share of net income from joint venture
United States	$	(263,499	)	$	(71,603	)	$	(39,160	)
Foreign	2,465			12,730			8,294
Total	$	(261,034	)	$	(58,873	)	$	(30,866	)

Total income tax benefit was as follows:



	Year Ended December 31,
	2018			2017			2016
Current taxes:
U.S. Federal	$	8,150		$	(47,916	)	$	(2,595	)
State	584			(12,226		)	679
Foreign	3,086			4,310			2,004
Total current tax expense (benefit)	11,820			(55,832		)	88
Deferred taxes:
U.S. Federal	$	(16,129	)	$	(25,017	)	$	(9,679	)
State	(780		)	3,009			(6,406		)
Deferred tax valuation allowance	(3,565		)	710			1,882
Foreign	(2,303		)	(1,896		)	(1,323		)
Total deferred tax benefit	(22,777		)	(23,194		)	(15,526		)
Total income tax benefit	$	(10,957	)	$	(79,026	)	$	(15,438	)

A reconciliation of income taxes based on the U.S. federal statutory income tax rate is summarized as follows:



	Year Ended December 31,
	2018		2017		2016
U.S federal statutory income tax rate	21.0	%	35.0	%	34.0	%
Change in valuation allowance	(0.9	)%	(1.2	)%	(6.1	)%
Foreign tax credits, exclusive of tax reform	—	%	(13.8	)%	8.2	%
State taxes, net of federal taxes, exclusive of tax reform	0.4	%	9.1	%	5.7	%
Non-U.S. earnings taxed at different rates	1.2	%	1.7	%	4.8	%
Non-deductible mergers and acquisitions costs	(0.2	)%	—	%	—	%
GILTI	(0.3	)%	—	%	—	%
Goodwill impairment	(15.5	)%	—	%	—	%
R&D Tax credit	0.3	%	0.3	%	0.9	%
Change in uncertain tax positions	0.3	%	(0.4	)%	3.2	%
Impact of Tax Reform
Toll Charge, net of foreign tax credit	0.6	%	(11.5	)%	—	%
Remeasurement of deferred taxes pursuant to tax reform	(0.9	)%	65.6	%	—	%
Tax Reform impact on divestiture of business segment	—	%	33.9	%	—	%
Section 199/Domestic Production Deduction	—	%	0.8	%	—	%
Divestiture of Business Segment, exclusive of tax reform	(0.9	)%	13.6	%	—	%
Return to provision	(0.8	)%	—	%	—	%
Prior period revisions	—	%	0.5	%	4.2	%
Foreign JV net income	—	%	—	%	(4.1	)%
Other adjustments, net	(0.1	)%	0.6	%	(0.8	)%
Effective tax rate	4.2	%	134.2	%	50.0	%

The 2018 effective tax rate of 4.2% differs from the U.S. federal statutory income tax rate of 21% due to permanent differences including the impact of the goodwill impairment, most of which is treated as a permanent difference for income tax purposes.

The 2017 effective tax rate of 134.2% was heavily influenced by the remeasurement of our ending domestic deferred balances, an estimate of the one-time transition tax (net of foreign tax credits) on earnings of our foreign subsidiaries in accordance with the Tax Act, and the impact of the Tax Act on the divestiture of the PBC Business.

The principal components of the deferred tax assets and liabilities are as follows:



	As of December 31,
	2018			2017
Deferred income tax liabilities:
Tax in excess of book depreciation	$	37,425		$	34,143
Goodwill	—			58
Intangible assets	80,623			50,688
Other deferred tax liabilities	794			389
Total deferred income tax liabilities	118,842			85,278
Deferred income tax assets:
Interest expense limitation	9,968			—
Goodwill	1,441			2,067
Inventories	2,745			2,248
Pension/Personnel accruals	1,317			1,596
Net operating loss carry forwards	9,321			6,950
Foreign tax credits	5,345			—
Credit carry forwards	4,130			3,427
Accruals and reserves	1,531			2,015
Other deferred tax assets	4,022			3,019
Deferred income tax assets before Valuation Allowance	39,820			21,322
Valuation allowance on deferred tax assets	(14,460		)	(7,608		)
Total deferred income tax assets	25,360			13,714
Net deferred income tax liabilities ⁽¹⁾	$	93,482		$	71,564

________________________


(1)	In accordance with the Tax Act, our ending domestic deferred balances have been remeasured to 21% for the year ended December 31, 2017.

During the year ended December 31, 2018, we finalized our accounting policy decision with respect to the new GILTI tax rules and have concluded that GILTI will be treated as a periodic charge in the year in which it arises. Therefore, we will not record deferred taxes for the basis associated with GILTI earnings.

As realization of certain deferred tax assets is not assured, management believes it is more likely than not that those net deferred tax assets will be realized. However, the amount of the deferred tax assets considered realizable could be reduced based on changing conditions.

The following table summarizes our total valuation allowances:



	Year Ended December 31,
	2018		2017		2016
Balance at beginning of year	$	7,608	$	4,090	$	2,376
Additions	6,852		3,518		1,882
Recoveries	—		—		(168		)
Balance at end of year	$	14,460	$	7,608	$	4,090

During 2018, the valuation allowance increased by approximately $6.9 million, as a result of an increase in foreign and state NOL’s and U.S. foreign tax credits.

During 2017, the valuation allowance increased by approximately $3.5 million, consisting of a $2.3 million increase due to the uncertainty of realizing certain state NOL carryforwards, and a $1.2 million increase for foreign NOL’s.

During 2016, the valuation allowance increased by approximately $1.7 million, consisting of a $1.9 million increase due to the uncertainty of realizing certain state NOL carryforwards offset by a decrease of $0.2 million related to the Company’s expectation that it is more likely than not that it will generate future taxable income to utilize this amount of net deferred tax assets.

A reconciliation of the beginning and ending amounts of unrecognized tax benefits, excluding interest and penalties, is as follows:



	Year Ended December 31,
	2018			2017			2016
Balance at beginning of year	$	5,655		$	4,741		$	5,724
Additions for tax positions of prior years	304			1,404			179
Reductions for tax positions of prior years	(1,350		)	(490		)	(1,162		)
Balance at end of year	$	4,609		$	5,655		$	4,741

As of December 31, 2018, the $4.6 million of unrecognized tax benefits would, if recognized, impact our effective tax rate by $4.0 million. The 2018 reduction is related to expiring statutes of limitations in certain US state and foreign jurisdictions.

Interest and penalties related to federal, state, and foreign income tax matters are recorded as a component of the provision for income taxes in our Consolidated Statements of Operations and Comprehensive Income (Loss). During 2018, we released less than $0.1 million of previously accrued foreign interest and released $0.2 million of previously accrued U.S. interest. During 2017, we released $0.2 million of previously accrued U.S. interest. During 2016, we released less than $0.1 million of previously accrued foreign interest and accrued $0.2 million in U.S. interest.

Management believes that it is reasonably possible that the amount of unrecognized income benefits and interest may decrease during the next twelve months by approximately $1.8 million, related to the expiration of the statutes of limitations.

As of December 31, 2018, the Company has $101.6 million of state NOL carryovers. The state NOL’s begin to expire in 2030. We also have $10.7 million of foreign NOL carryovers at December 31, 2018. The foreign NOL’s have an indefinite life. The Company has $4.1 million of tax credits in foreign jurisdictions at December 31, 2018. The tax credits in foreign jurisdictions begin to expire in 2026. The Company has foreign tax credit carryforwards for federal income tax purposes of $5.3 million at December 31, 2018. The foreign tax credit carryforwards begin to expire in 2024. The state NOL’s, tax credits in foreign jurisdictions, and foreign tax credits for federal income tax purposes have a full valuation allowance. These amounts are included in the valuation allowance table on the previous page.

We or our subsidiaries file income tax returns in the U.S. federal jurisdiction, and in various states and foreign jurisdictions. During the third quarter of 2017, the Internal Revenue Service commenced an examination of the federal tax return for the pre-acquisition period of January 1, 2015, through October 19, 2015, for Precision Engineered Products, LLC, our wholly-owned subsidiary. The examination was completed during the 4th quarter of 2018.

The Company is no longer subject to federal examinations by tax authorities for years before 2012. The Company is also subject to examination by various state and international tax authorities. The tax years subject to examination vary by jurisdiction. The Company regularly assesses the outcomes of both ongoing and future examinations for the current or prior years to ensure the Company’s provision for income taxes is sufficient. The Company recognizes liabilities based on estimates of whether additional taxes will be due and believes its reserves are adequate in relation to any potential assessments. The outcome of any one examination, some of which may conclude during the next twelve months, is not expected to have a material impact on the Company’s financial position or results of operations.

We operate under tax holidays in other countries, which are effective through December 31, 2026, and may be extended if certain additional requirements are satisfied. The tax holidays are conditional upon our meeting certain employment and investment thresholds. The impact of these tax holidays decreased foreign taxes by $0.8 million and $0.7 million for 2017 and 2016, respectively. The benefit of the tax holidays on net income per share (diluted) was $0.03 and $0.03 for 2017, and 2016, respectively. The tax holidays had no impact on our 2018 foreign taxes.

Debt

12 Months Ended

Dec. 31, 2018

Debt Disclosure [Abstract]

Debt

Collectively, our credit facility is comprised of a term loan with a face amount of $545.0 million, maturing on October 19, 2022 (the “Senior Secured Term Loan”); a term loan with a face amount of $300.0 million, maturing on April 3, 2021 (the “Incremental Term Loan”); and a revolving line of credit with a face amount of $143.0 million, maturing on October 19, 2020 (the “Senior Secured Revolver”). The credit facility is collateralized by all of our assets.

The following table presents outstanding debt balances as of December 31, 2018 and 2017.



	As of December 31,
	2018		2017
Senior Secured Term Loan	$	532,063	$	534,250
Incremental Term Loan	279,000		291,000
Senior Secured Revolver	38,720		—
International lines of credit and other loans	9,810		3,315
Total principal	859,593		828,565
Less—current maturities of long-term debt	31,280		17,283
Principal, net of current portion	828,313		811,282
Less—unamortized debt issuance costs	16,842		20,477
Long-term debt, net of current portion	$	811,471	$	790,805

We capitalized interest costs amounting to $1.2 million, $1.1 million, and $1.6 million in the years ended December 31, 2018, 2017, and 2016, related to construction in progress.

Senior Secured Term Loan

On November 24, 2017, we amended our existing credit facility to reduce the applicable margin on outstanding borrowings under the Senior Secured Term Loan by 50 basis points from 4.25% to 3.75%. Outstanding borrowings under the Senior Secured Term Loan bear interest at the greater of 0.75% or one-month London Interbank Offered Rate (“LIBOR”) plus an applicable margin of 3.75%. At December 31, 2018, the Senior Secured Term Loan bore interest of 6.25%.

Incremental Term Loan

On November 24, 2017, we amended our existing credit facility to reduce the applicable margin on outstanding borrowings under the Incremental Term Loan by 50 basis points from 3.75% to 3.25%. Outstanding borrowings under the Incremental Term Loan bear interest at one-month LIBOR plus an applicable margin of 3.25%. At December 31, 2018, the Incremental Term Loan bore interest of 5.75%, one-month LIBOR plus 3.25%.

Second Lien Credit Agreement

On May 7, 2018, we amended our existing credit facility (the “May 2018 amendment”) to permit the Paragon Medical acquisition, to permit the Second Lien Credit Agreement, and to amend certain covenants. In connection with the May 2018 amendment, we, certain of our subsidiaries named therein, SunTrust Bank, as Administrative Agent, SunTrust Robinson Humphrey, Inc., as Lead Arranger and Bookrunner, and the lenders named therein, entered into a Second Lien Credit Agreement (the “Second Lien Credit Agreement”) pursuant to which SunTrust Bank and the other lenders extended to us a $200.0 million secured second lien term loan facility (the “Second Lien Facility”). We utilized the net proceeds from the Second Lien Facility, together with cash on hand, to pay the Paragon Medical purchase price and fees and expenses related to the acquisition. The Second Lien Facility was collateralized by all of our assets and had a maturity date of April 19, 2023. Outstanding borrowings under the Second Lien Facility bore interest at either (i) a base rate plus an applicable margin of 7.00%, or (ii) the greater of LIBOR or 1.00% plus an applicable margin of 8.00%. We paid $16.7 million of debt issuance costs related to the May 2018 amendment of which $12.9 million is included in the “Loss on extinguishment of debt and write-off of debt issuance costs” line on the Consolidated Statements of Operations and Comprehensive Income (Loss) and $3.8 million is capitalized as a reduction of long-term debt.

On September 18, 2018, a significant portion of net proceeds from a registered public offering of shares of our common stock was used to voluntarily prepay in the full the $200.0 million outstanding principal balance. We paid a prepayment penalty of two percent of the outstanding principal balance, or $4.0 million, and wrote off $2.6 million of unamortized debt issuance costs to the “Loss on extinguishment of debt and write-off of debt issuance costs” line on the Consolidated Statements of Operations and Comprehensive Income (Loss). Refer to Note 15 for additional information regarding the registered public offering.

Senior Secured Revolver

Outstanding borrowings under the Senior Secured Revolver bear interest at one-month LIBOR plus 3.50%. At December 31, 2018, the Senior Secured Revolver bore interest of 6.00%. We pay an annual commitment fee of 0.50% for unused capacity under the Senior Secured Revolver on a quarterly basis.

On December 26, 2018, we amended our existing credit facility (the “December 2018 amendment”) to increase the total available capacity under the Senior Secured Revolver and to reduce the consolidated net leverage ratio, the basis for certain financial covenants, for periods ended on or after December 31, 2018. The December 2018 amendment increased the total available capacity under the Senior Secured Revolver from $100.0 million to $125.0 million. We paid $0.1 million of debt issuance costs related to the December 2018 amendment which is capitalized as a reduction of long-term debt.

Total available capacity under the Senior Secured Revolver was $125.0 million as of December 31, 2018. Available capacity may be restored to $143.0 million upon the achievement of certain requirements. Our credit facility is subject to certain financial covenants based on a consolidated net leverage ratio, as defined in the credit facility agreement. The financial covenants are effective when we have outstanding borrowings under our Senior Secured Revolver on the last day of any fiscal quarter and become more restrictive over time. We had $38.7 million outstanding under the Senior Secured Revolver at December 31, 2018, and we were in compliance with all covenants under our credit facility.

International Lines of Credit and Other Loans

International lines of credit and other loans is comprised of loans with financial institutions in France, Brazil, and China (“international credit facilities”). The international credit facilities are used to fund working capital and equipment purchases for our manufacturing plants in those countries. As of December 31, 2018, the international credit facilities had $9.8 million outstanding of which $6.8 million is classified as “Current maturities of long-term debt” on the Consolidated Balance Sheets.

Future Maturities

The following table lists aggregate maturities of long-term debt for the next five years and thereafter.



Year Ending December 31,	Aggregate Maturities Principal Amounts
2019	$	31,280
2020	50,097
2021	261,094
2022	515,157
2023	344
Thereafter	1,621

Total outstanding principal	$	859,593

Restructuring and Integration

12 Months Ended

Dec. 31, 2018

Restructuring and Related Activities [Abstract]

Restructuring and Integration

The following table summarizes restructuring and integration charges for the years ended December 31, 2018, 2017, and 2016.



	Mobile Solutions		Power Solutions		Life Sciences		Corporate and Consolidations		Total
Year Ended December 31, 2018
Severance and other employee costs	$	—	$	—	$	1,336	$	728	$	2,064
Site closure and other associated costs	63		—		—		—		63
Total	$	63	$	—	$	1,336	$	728	$	2,127
Year Ended December 31, 2017
Severance and other employee costs	$	17	$	—	$	—	$	—	$	17
Site closure and other associated costs	369		—		—		—		369
Total	$	386	$	—	$	—	$	—	$	386
Year Ended December 31, 2016
Severance and other employee costs	$	851	$	455	$	381	$	—	$	1,687
Site closure and other associated costs	3,488		263		220		—		3,971
Total	$	4,339	$	718	$	601	$	—	$	5,658

The following tables summarize restructuring and integration reserve activity for the years ended December 31, 2018, 2017, and 2016.



	Reserve Balance as of December 31, 2017		Charges		Non-cash Adjustments			Cash Reductions			Reserve Balance as of December 31, 2018
Severance and other employee costs	$	—	$	2,064	$	—		$	(942	)	$	1,122
Site closure and other associated costs	1,099		63		(56		)	(1,082		)	24
Total	$	1,099	$	2,127	$	(56	)	$	(2,024	)	$	1,146

	Reserve Balance as of December 31, 2016		Charges		Non-cash Adjustments			Cash Reductions			Reserve Balance as of December 31, 2017
Severance and other employee costs	$	1,000	$	17	$	(164	)	$	(853	)	$	—
Site closure and other associated costs	1,625		369		—			(895		)	1,099
Total	$	2,625	$	386	$	(164	)	$	(1,748	)	$	1,099

	Reserve Balance as of December 31, 2015		Charges		Non-cash Adjustments			Cash Reductions			Reserve Balance as of December 31, 2016
Severance and other employee costs	$	887	$	1,687	$	(278	)	$	(1,296	)	$	1,000
Site closure and other associated costs	1,845		3,971		(2,142		)	(2,049		)	1,625
Total	$	2,732	$	5,658	$	(2,420	)	$	(3,345	)	$	2,625

In 2018, we recognized severance and other employee costs of $0.7 million at corporate headquarters related to the restructuring of our former Precision Engineered Products Group to form the Power Solutions and Life Sciences groups, effective January 2, 2018. We also recognized severance and other employee costs of $1.3 million in our Life Sciences group related to the post-acquisition integration of Paragon Medical into our existing business.

In 2017, we recognized restructuring and integration expense of $0.4 million in our Mobile Solutions group due primarily to the closure of a plant in Wheeling, Illinois (the “Wheeling Plant”), which was a part of our integration plan after the acquisition of Autocam Corporation (“Autocam”) in 2014.

In 2016, we recognized restructuring and integration expense of $4.3 million in our Mobile Solutions segment due primarily to the closure of the Wheeling Plant. These charges consisted of $0.8 million of severance and other employee costs and site closure and other associated costs of $3.5 million. We also recognized restructuring and integration expense of $0.7 million and $0.6 million due to initiatives within our Power Solutions and Life Sciences groups, respectively, related to integration costs, rebranding, site moving costs for two plants, and other employee costs.

The amount accrued as of December 31, 2018, for restructuring and integration costs represents our expected obligation over the next 2.2 years primarily related to severance and other employee costs. We expect to pay $0.7 million within the next twelve months.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Lease Payments

We have operating lease commitments for machinery, office equipment, vehicles, and manufacturing and office space which expire on varying dates. We recognized rent expense of $12.4 million, $7.6 million, and $7.2 million for the years ended December 31, 2018, 2017 and 2016, respectively.

The following table summarizes future minimum lease payments as of December 31, 2018, under operating leases that have initial or remaining non-cancelable lease terms in excess of one year.



Year Ending December 31,	Minimum Rental Commitments
2019	$	13,337
2020	11,515
2021	10,557
2022	10,293
2023	8,752
Thereafter	53,945

Total minimum payments	$	108,399

Brazil ICMS Tax Matter

Prior to the acquisition of Autocam in 2014, Autocam’s Brazilian subsidiary (“Autocam Brazil”) received notification from the Brazilian tax authority regarding ICMS (state value added tax or “VAT”) tax credits claimed on intermediary materials (e.g. tooling and perishable items) used in the manufacturing process. The Brazilian tax authority notification disallowed state ICMS tax credits claimed on intermediary materials based on the argument that these items are not intrinsically related to the manufacturing process. Autocam Brazil filed an administrative defense with the Brazilian tax authority arguing, among other matters, that it should qualify for an ICMS tax credit, contending that the intermediary materials are directly related to the manufacturing process.

We believe that we have substantial legal and factual defenses, and we plan to defend our interests in this matter vigorously. The matter encompasses several lawsuits filed with Brazilian courts requesting declaratory actions that no tax is due or seeking a stay of execution on the collection of the tax. In 2018, we obtained a favorable decision in one of the declaratory actions for which the period for appeal has expired. We have filed actions in each court requesting dismissal of the matter based on the earlier court action. Although we anticipate a favorable resolution to all matters, we can provide no assurances that we will be successful in achieving dismissal of all pending cases. While we believe a loss is not probable, we estimate the range of possible losses related to this assessment is from $0 to $6.0 million. No amount was accrued at December 31, 2018, for this matter.

We are entitled to indemnification from the former shareholders of Autocam, subject to the limitations and procedures set forth in the agreement and plan of merger relating to the Autocam acquisition. Management believes the indemnification would include amounts owed for the tax, interest, and penalties related to this matter.

All Other Legal Matters

All other legal proceedings are of an ordinary and routine nature and are incidental to our operations. Management believes that such proceedings should not, individually or in the aggregate, have a material adverse effect on our business, financial condition, results of operations, or cash flows. In making that determination, we analyze the facts and circumstances of each case at least quarterly in consultation with our attorneys and determine a range of reasonably possible outcomes.

Equity Offering	12 Months Ended
Equity Offering	Dec. 31, 2018
Text Block [Abstract]
Equity Offering	Equity Offering On September 18, 2018, we issued 14.4 million shares of our common stock in a public offering under our shelf registration statement at a price of $16.00 per share. Net proceeds of $217.3 million were used to repay the Second Lien Facility and a portion of the Senior Secured Revolver.

Revenue from Contracts with Customers

12 Months Ended

Dec. 31, 2018

Revenue from Contract with Customer [Abstract]

Revenue from Contract with Customers

Revenue from Contracts with Customers

We adopted ASC 606 on January 1, 2018, using the modified retrospective transition method for all contracts not completed as of the date of adoption. The reported results for 2018 reflect the application of ASC 606 while the reported results for 2017 and 2016 were prepared under the guidance of ASC 605. The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of our goods and will provide financial statement readers with enhanced disclosures. In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods in an amount that reflects the consideration we expect to be entitled to receive in exchange for those goods. To the extent that transaction price includes variable consideration, we estimate the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount method depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in management’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will occur.

Revenue is recognized when control of the good or service is transferred to the customer either at a point in time or, in limited circumstances, as our services are rendered over time. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or services.

The following tables summarize sales to external customers by operating segment for the years ended December 31, 2018, 2017, and 2016.



	Year Ended December 31, 2018
	Mobile Solutions		Power Solutions		Life Sciences		Intersegment Sales Eliminations			Total
United States	$	187,178	$	157,357	$	206,776	$	(2,331	)	$	548,980
China	43,610		5,537		6,130		—			55,277
Mexico	27,053		12,254		191		—			39,498
Brazil	35,314		215		29		—			35,558
Germany	5,652		26		19,870		—			25,548
Switzerland	5,006		54		6,446		—			11,506
Poland	7,010		13		8		—			7,031
Italy	5,558		221		317		—			6,096
Czech Republic	6,131		47		—		—			6,178
Netherlands	—		3,290		—		—			3,290
Other	12,525		10,764		8,406		—			31,695
Total net sales	$	335,037	$	189,778	$	248,173	$	(2,331	)	$	770,657



	Year Ended December 31, 2017
	Mobile Solutions		Power Solutions		Life Sciences		Intersegment Sales Eliminations			Total
United States	$	190,828	$	152,938	$	96,062	$	(1,990	)	$	437,838
China	45,503		6,481		267		—			52,251
Mexico	26,639		14,220		78		—			40,937
Brazil	35,425		185		—		—			35,610
Germany	5,502		11		35		—			5,548
Switzerland	5,450		—		—		—			5,450
Poland	5,183		—		—		—			5,183
Italy	5,347		334		—		—			5,681
Czech Republic	—		—		—		—			—
Netherlands	—		2,817		—		—			2,817
Other	16,975		9,616		1,887		—			28,478
Total net sales	$	336,852	$	186,602	$	98,329	$	(1,990	)	$	619,793



	Year Ended December 31, 2016
	Mobile Solutions		Power Solutions		Life Sciences		Intersegment Sales Eliminations			Total
United States	$	196,217	$	134,564	$	78,707	$	(1,571	)	$	407,917
China	44,579		8,131		403		—			53,113
Mexico	24,919		20,944		—		—			45,863
Brazil	23,801		458		—		—			24,259
Germany	4,497		8		35		—			4,540
Switzerland	—		—		—		—			—
Poland	—		—		—		—			—
Italy	5,027		322		—		—			5,349
Czech Republic	—		—		—		—			—
Netherlands	—		1,882		—		—			1,882
Other	27,098		14,021		912		—			42,031
Total net sales	$	326,138	$	180,330	$	80,057	$	(1,571	)	$	584,954

Product Sales

We generally transfer control and recognize a sale when we ship the product from our manufacturing facility to our customer, at a point in time, as this is when our customer obtains the ability to direct use of, and obtain substantially all of the remaining benefits from, the goods. We have elected to recognize the cost for freight and shipping when control over products has transferred to the customer as a component of cost of sales.

We use an observable price to determine the stand-alone selling price for separate performance obligations or a cost-plus-margin approach when an observable price is not available. The expected duration of our contracts is one year or less, and we have elected to apply the practical expedient that allows entities to disregard the effects of financing when the contract length is less than one year. The amount of consideration we receive and the revenue we recognize varies with volume rebates and incentives we offer to our customers. We estimate the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount method depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur.

We have utilized certain practical expedients allowed by the new standard. We utilize the portfolio approach practical expedient to evaluate sales-related discounts on a portfolio basis to contracts with similar characteristics. The effect on our financial statements of applying the portfolio approach would not differ materially from applying the new standard to individual contracts.

We give our customers the right to return only defective products in exchange for functioning products or rework of the product. These transactions are evaluated and accounted for under ASC Topic 460, Guarantees, and we estimate the impact to the transaction price based on an analysis of historical experience.

Other Sources of Revenue

We provide pre-production activities related to engineering efforts to develop molds, dies, and machines that are owned by our customers. We may receive advance payments from customers which are deferred until satisfying our performance obligations by compliance with customer-specified milestones, recognizing revenue at a point in time. These contracts generally have an original expected duration of less than one year.

The following table provides information about contract liabilities from contracts with customers.



	Deferred Revenue
Balance at January 1, 2018	$	2,124
Balance at December 31, 2018	$	2,974

The timing of revenue recognition, billings, and cash collections results in billed accounts receivable and customer advances and deposits (e.g. contract liability) on the Consolidated Balance Sheets. These contract liabilities are reported on the Consolidated Balance Sheets on a contract-by-contract basis at the end of each reporting period as deferred revenue. Deferred revenue relates to payments received in advance of performance under the contract and recognized as revenue as (or when) we perform under the contract. Changes in the contract liability balances during the year ended December 31, 2018, were not materially impacted by any other factors. Revenue recognized for the year ended December 31, 2018, from amounts included in deferred revenue at the beginning of the period for performance obligations satisfied or partially satisfied during the year ended December 31, 2018, was approximately $1.9 million.

Transaction Price Allocated to Future Performance Obligations

ASC 606 requires that we disclose the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied as of December 31, 2018. The guidance provides certain practical expedients that limit this requirement. Our contracts meet the following practical expedient provided by ASC 606:


•	The performance obligation is part of a contract that has an original expected duration of one year or less.

Costs to Obtain and Fulfill a Contract

Prior to the adoption of ASC 606, we expensed commissions paid to internal sales representative for obtaining contracts. Under ASC 606, we adopted the practical expedient to recognize commissions paid to internal sales personnel that are incremental to obtaining customer contracts as an expense when incurred since the amortization period is less than one year. The judgments made in determining the amount of costs incurred included whether the commissions are in fact incremental and would not have occurred absent the customer contract. Costs to obtain a contract are expressed as selling, general and administrative expense.

Sales, VAT, and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. Incidental items that are immaterial in the context of the contract are recognized as expense.

Financial Statement Impact of Adopting ASC 606

The following table presents the impact of adoption of ASC 606 on our Consolidated Statements of Operations and Comprehensive Income (Loss) and our Consolidated Balance Sheets. Differences are due to the acceleration in the recognition of revenue to the point of shipment or delivery for contracts where an unconditional obligation to purchase is present for inventory that was considered in consignment under ASC 605.



	Year Ended December 31, 2018
	As Reported			Balances Without Adoption of ASC 606			Effect of Change
Net sales	$	770,657		$	770,654		$	3
Cost of sales	588,205			588,202			3
Income (loss) from operations	(178,888		)	(178,888		)	—



	As of December 31, 2018
	As Reported		Balances Without Adoption of ASC 606		Effect of Change
Accounts receivable, net	$	133,421	$	132,810	$	611
Inventories	122,615		122,988		(373		)

Share-Based Compensation

12 Months Ended

Dec. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-Based Compensation

We recognize compensation expense of all employee and non-employee director share-based compensation awards in the financial statements based upon the grant date fair value of the awards over the requisite service or vesting period, less any expense incurred for estimated forfeitures. As of December 31, 2018, we have approximately 1.9 million maximum shares that can be issued as options, stock appreciation rights, and other share-based awards. Shares of our common stock delivered upon exercise or vesting may consist of newly issued shares of our common stock or shares acquired in the open market.

Share-based compensation expense is recognized in the “Selling, general and administrative expense” line in the Consolidated Statements of Operations and Comprehensive Income (Loss) except for $1.0 million and $0.5 million attributable to discontinued operations for the years ended December 31, 2017 and 2016, respectively.

The following table lists the components of share-based compensation expense by type of award.



	Year Ended December 31,
	2018			2017		2016
Stock options	$	678		$	1,078	$	687
Restricted stock	1,630			1,968		2,061
Performance share units	2,076			2,450		1,187
Change in estimate of performance share vesting ⁽¹⁾	(1,968		)	—		—
Share-based compensation expense	$	2,416		$	5,496	$	3,935

_______________________

(1) Amount reflects the decrease in share-based compensation expense of $2.0 million based on the change in estimate of the probability of vesting of performance share units as described in the “Performance Share Units” section of this Note.

The total tax benefit for share-based compensation cost was $0.7 million, $1.6 million, and $0.6 million for the years ended December 31, 2018, 2017, and 2016, respectively. Unrecognized compensation cost related to unvested awards was $4.0 million as of December 31, 2018. We expect that cost to be recognized over a weighted-average period of 1.8 years.

Stock Options

Option awards are typically granted to key employees on an annual basis. A single option grant is typically awarded to eligible employees each year by the Compensation Committee of the Board of Directors. The Compensation Committee occasionally awards additional individual grants to eligible employees. All employees are awarded options at an exercise price equal to the closing price of our stock on the date of grant. The term life of options is ten years with a vesting period of generally three years.

During the years ended 2018, 2017, and 2016, we granted options to purchase 57,800, 125,700, and 167,000 shares, respectively, to certain key employees. The weighted average grant date fair value of the options granted during 2018, 2017, and 2016 was $10.60, $11.84, and $5.02 per share, respectively. The fair value of our options cannot be determined by market value because they are not traded in an open market. Accordingly, we utilized the Black Scholes financial pricing model to estimate the fair value.

The following table shows the weighted average assumptions relevant to determining the fair value of stock options granted in each year.



	2018		2017		2016
Expected term	6 years		6 years		6 years
Average risk-free interest rate	2.66	%	2.03	%	1.43	%
Expected dividend yield	1.15	%	1.16	%	2.48	%
Expected volatility	47.69	%	56.56	%	59.23	%
Expected forfeiture rate	4.00	%	3.00	%	3.00	%

The expected term is derived from using the simplified method of determining stock option terms as described under the SAB Topic 14, Share-based payment. The simplified method was used because sufficient historical stock option exercise experience was not available.

The average risk-free interest rate is derived from United States Department of Treasury published interest rates of daily yield curves for the same time period as the expected term.

The expected dividend yield is derived by a mathematical formula which uses the expected annual dividends over the expected term divided by the fair market value of our common stock at the grant date.

The expected volatility is derived from our actual common stock historical volatility over the same time period as the expected term. The expected volatility rate is derived by mathematical formula utilizing daily closing price data.

The expected forfeiture rate is determined from examining the historical pre-vesting forfeiture patterns of past option issuances to key employees. While the expected forfeiture rate is not an input of the Black Scholes financial pricing model for determining the fair value of the options, it is an important determinant of stock option compensation expense to be recorded.

The following table summarizes stock option activity for the year ended December 31, 2018.



	Number of Options (in thousands)		Weighted- Average Exercise Price (per share)		Weighted- Average Remaining Contractual Term (years)	Aggregate Intrinsic Value
Outstanding at January 1, 2018	746		$	14.33
Granted	58		24.47
Exercised	(27	)	10.15			$	477
Forfeited or expired	(6	)	22.39
Outstanding at December 31, 2018	771		$	15.17	5.6	$	—	⁽¹⁾
Exercisable at December 31, 2018	625		$	13.63	4.9	$	—	⁽¹⁾


(1)	The aggregate intrinsic value is the sum of intrinsic values for each exercisable individual option grant. The intrinsic value is the amount by which the closing market price of our stock at December 31, 2018, was greater than the exercise price of any individual option grant.

Cash proceeds from the exercise of options in the years ended December 31, 2018, 2017, and 2016 totaled approximately $0.3 million, $3.1 million, and $2.8 million, respectively. The tax benefit recognized from stock option exercises was less than $0.1 million, $0.2 million, and less than $0.1 million in the years ended December 31, 2018, 2017, and 2016, respectively. For the years ended December 31, 2018, 2017, and 2016, proceeds from stock options are presented exclusive of tax benefits in cash flows from financing activities in the Consolidated Statements of Cash Flows. The total intrinsic value of options exercised during the years ended December 31, 2018, 2017, and 2016 was $0.5 million, $3.8 million, and $2.9 million, respectively.

Restricted Stock

During the years ended December 31, 2018, 2017, and 2016, we granted 86,516, 85,393, and 152,510 restricted stock awards to non-executive directors, officers, and certain other key employees. The restricted stock granted during the years ended 2018, 2017, and 2016, vest pro-rata over three years for officers and certain other key employees and over one year for non-executive directors. We determined the fair value of the shares awarded by using the closing price of our common stock as of the date of grant. The weighted average grant date fair value of restricted stock granted in the years ended December 31, 2018, 2017, and 2016, was $24.55, $24.29, and $11.39 per share, respectively. The total grant date fair value of restricted stock that vested in the years ended December 31, 2018, 2017, and 2016, was $1.8 million, $2.1 million, and $2.6 million, respectively.

The following table summarizes unvested restricted stock award activity for the year ended December 31, 2018.



	Number of Unvested Restricted Shares (in thousands)		Weighted Average Grant Date Fair Value
Unvested at January 1, 2018	152		$	19.21
Granted	87		24.55
Vested	(93	)	19.69
Forfeited	—		—
Unvested at December 31, 2018	146		$	22.07

Performance Share Units

Performance Share Units (“PSUs”) are a form of long-term incentive compensation awarded to executive officers and certain other key employees designed to directly align the interests of employees to the interests of our stockholders, and to create long-term stockholder value. PSUs granted in 2018 and 2017 were made pursuant to the NN, Inc. 2016 Omnibus Incentive Plan and a Performance Share Unit Agreement (the “2016 Omnibus Agreement”). PSUs granted in 2016 were made pursuant to the NN, Inc. 2011 Stock Incentive Plan and a Performance Share Unit Agreement (the “2011 Stock Agreement”). Some PSUs are based on total shareholder return (“TSR Awards”), and other PSUs are based on return on invested capital (“ROIC Awards”).

The TSR Awards vest, if at all, upon our achieving a specified relative total shareholder return, which will be measured against the total shareholder return of the S&P SmallCap 600 Index during specified performance periods as defined in the 2016 Omnibus Agreement and the 2011 Stock Agreement. The ROIC Awards will vest, if at all, upon our achieving a specified average return on invested capital during the performance periods. Each performance period generally begins on January 1 of the year of grant and ends 36 months later on December 31.

We recognize compensation expense over the performance period in which the performance and market conditions are measured. If the PSUs do not vest at the end of the performance periods, then the PSUs will expire automatically. Upon vesting, the PSUs will be settled by the issuance of shares of our common stock, subject to the executive officer’s continued employment. The actual number of shares of common stock to be issued to each award recipient at the end of the performance periods will be interpolated between a threshold and maximum payout amount based on actual performance results. No dividends will be paid on outstanding PSUs during the performance period; however, dividend equivalents will be paid based on the number of shares of common stock that are ultimately earned at the end of the performance periods.

With respect to the TSR Awards, a participant will earn 50% of the target number of PSUs for “Threshold Performance,” 100% of the target number of PSUs for “Target Performance,” and 150% of the target number of PSUs for “Maximum Performance.” With respect to the ROIC Awards, a participant will earn 35% of the target number of PSUs for “Threshold Performance,” 100% of the target number of PSUs for “Target Performance,” and 150% of the target number of PSUs for “Maximum Performance.” For performance levels falling between the values shown below, the percentages will be determined by interpolation.

The following table presents the goals with respect to TSR Awards and ROIC Awards granted in 2018, 2017, and 2016.



ROIC Awards:	Threshold Performance (35% of Shares)		Target Performance (100% of Shares)		Maximum Performance (150% of Shares)
2018 grants	15.5	%	18.0	%	19.5	%
2017 grants	15.0	%	17.5	%	20.0	%
2016 grants	15.5	%	18.0	%	20.5	%

We estimate the grant date fair value of TSR Awards using the Monte Carlo simulation model, as the total shareholder return metric is considered a market condition under ASC Topic 718, Compensation – stock compensation. The grant date fair value of ROIC Awards is based on the closing price of a share of our common stock on the date of grant.

The following table presents the number of awards granted and the grant date fair value of each award in the periods presented.



	TSR Awards			ROIC Awards
Award Year	Number of Shares (in thousands)	Grant Date Fair Value (per share)		Number of Shares (in thousands)	Grant Date Fair Value (per share)
2018	55	$	24.65	55	$	24.55
2017	46	$	29.84	53	$	24.20
2016	101	$	9.38	101	$	11.31

We recognize expense for ROIC Awards based on the probable outcome of the associated performance condition. We generally recognize an expense for ROIC Awards based on the Target Performance threshold of 100% because, at the date of grant, the Target Performance is the probable level of performance achievement. During the year ended 2018, none of the ROIC Awards that were granted in 2016 vested as the performance achieved was below the “Threshold Performance” level of 15.5%, as defined by the grant agreement. For the year ended December 31, 2018, we recognized a decrease in share-based compensation expense of $0.8 million in the “Selling, general and administrative expense” line in the Consolidated Statements of Operations and Comprehensive Income (Loss) to reflect the change in vesting. Additionally, for the year ended December 31, 2018, we determined that the probability of performance achievement for ROIC Awards that were granted in 2017 and 2018 diminished to below the “Threshold Performance” level of 15.0% and 15.5%, respectively, as defined by the grant agreement. For the year ended December 31, 2018, we recognized a decrease in share-based compensation expense of $0.8 million and $0.4 million to reflect the change in estimate of the probability of vesting for the 2017 and 2018 ROIC Awards, respectively, in the “Selling, general and administrative expense” line in the Consolidated Statements of Operations and Comprehensive Income (Loss). Related accrued dividend equivalents of $0.1 million were also reversed in 2018 for the 2016, 2017, and 2018 awards .

The following table summarizes changes in unvested PSUs during the year ended December 31, 2018, and changes during the year then ended.



	Nonvested TSR Awards				Nonvested ROIC Awards
	Number of Shares (in thousands)		Weighted Average Grant Date Fair Value		Number of Shares (in thousands)		Weighted Average Grant Date Fair Value
Nonvested at January 1, 2018	130		$	16.60	136		$	16.27
Granted	55		24.65		55		24.55
Vested	—		—		—		—
Expired	(78	)	9.38		(77	)	11.31
Forfeited	(13	)	14.50		(14	)	14.86
Nonvested at December 31, 2018	94		$	26.84	100		$	24.39

No TSR Awards or ROIC Awards vested in 2018. The total grant date fair value of TSR Awards and ROIC Awards that vested in 2017 was $0.9 million and $1.2 million, respectively.

Accumulated Other Comprehensive Income	12 Months Ended
Accumulated Other Comprehensive Income	Dec. 31, 2018
Equity [Abstract]
Accumulated Other Comprehensive Income	Accumulated Other Comprehensive Income The majority of our Accumulated Other Comprehensive Income (“AOCI”) relates to foreign currency translation of our foreign subsidiary balances. During the year ended December 31, 2018, we had other comprehensive loss of $13.9 million due to foreign currency translations. During the year ended December 31, 2017, we had other comprehensive income of $22.1 million due to foreign currency translations. In connection with the sale of discontinued operations, we reclassified $9.2 million out of AOCI to discontinued operations on the Consolidated Statements of Operations and Comprehensive Income (Loss) in 2017. During the year ended December 31, 2016, we had other comprehensive loss of $10.6 million due to foreign currency translations and a net gain of $1.9 million due to change in fair value of the interest rate swap and discontinuation of hedge accounting. Amounts related to the interest rate swap were reclassified out of AOCI during 2016 upon discontinuation of hedge accounting.

Net Income (Loss) Per Share

12 Months Ended

Dec. 31, 2018

Earnings Per Share [Abstract]

Net Income (Loss) Per Share

The following table summarizes the computation of basic and diluted net income (loss) per share.



	Year Ended December 31,
	2018			2017		2016
Income (loss) from continuing operations	$	(264,467	)	$	25,364	$	(9,490	)
Income from discontinued operations, net of tax	—			137,688		16,153
Net income (loss)	$	(264,467	)	$	163,052	$	6,663

Weighted average shares outstanding	31,678			27,433		27,016
Effect of dilutive stock options	—			322		—
Diluted shares outstanding	31,678			27,755		27,016

Basic income (loss) from continuing operations per share	$	(8.35	)	$	0.92	$	(0.35	)
Basic income from discontinued operations per share	—			5.02		0.60
Basic net income (loss) per share	$	(8.35	)	$	5.94	$	0.25

Diluted income (loss) from continuing operations per share	$	(8.35	)	$	0.91	$	(0.35	)
Diluted income from discontinued operations per share	—			4.96		0.60
Diluted net income (loss) per share	$	(8.35	)	$	5.87	$	0.25
Cash dividends declared per common share	$	0.28		$	0.28	$	0.28

The calculations of diluted income (loss) from continuing operations per share for the years ended December 31, 2018, 2017, and 2016, exclude 0.4 million, 0.4 million, and 0.8 million potentially dilutive stock options and restricted stock units which had the effect of being anti-dilutive. Given the loss from continuing operations in 2018 and 2016, all options are considered anti-dilutive and were excluded from the calculation of diluted loss from continuing operations per share and diluted net income (loss) per share. Stock options excluded from the calculations of diluted income (loss) from continuing operations per share for the years ended December 31, 2018, 2017, and 2016, had a per share exercise price ranging from $4.42 to $25.16 in each respective year.

Fair Value Measurements	12 Months Ended
Fair Value Measurements	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Fair value is an exit price representing the expected amount that an entity would receive to sell an asset or pay to transfer a liability in an orderly transaction with market participants at the measurement date. We followed consistent methods and assumptions to estimate fair values as more fully described in Note 1. Our financial instruments that are subject to fair value disclosure consist of cash and cash equivalents, accounts receivable, accounts payable, short-term investments, and long-term debt. As of December 31, 2018, the carrying values of these financial instruments approximated fair value. The fair value of floating-rate debt approximates the carrying amount because the interest rates paid are based on short-term maturities. As of December 31, 2018, we had no fixed-rate debt outstanding. Fair value principles prioritize valuation inputs across three broad levels. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on the assumptions used to measure assets and liabilities at fair value. An asset or liability’s classification within the various levels is determined based on the lowest level input that is significant to the fair value measurement. We may manage our exposure to fluctuations in interest rates using a mix of fixed and variable rate debt. Historically, we have managed the exposure by entering into interest rate swap agreements which mitigate exposures to the risks and variability of our operating results. In 2016, we discontinued hedge accounting for an interest rate swap that was if effect at that time. Upon discontinuation of hedge accounting, all amounts in AOCI related to the interest rate swap were reclassified to earnings, and we began accounting for the interest rate swap on a mark-to-market basis. In 2017, we terminated the interest rate swap. As of December 31, 2018, we had no interest rate swaps outstanding. On February 8, 2019, the Company entered into a fixed-rate interest swap agreement as discussed in Note 22 to the consolidated financial statements.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Quarterly Results of Operations (Unaudited)

12 Months Ended

Dec. 31, 2018

Quarterly Financial Information Disclosure [Abstract]

Quarterly Results of Operations (Unaudited)

The following tables summarize the quarterly results of operations for the years ended December 31, 2018 and 2017.



2018	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
Net sales	$	169,148		$	196,349		$	205,683		$	199,477
Cost of sales (exclusive of depreciation and amortization)	126,444			148,640			156,408			156,713
Income (loss) from continuing operations	(5,983		)	(24,511		)	(13,784		)	(220,189		)
Net income (loss)	(5,983		)	(24,511		)	(13,784		)	(220,189		)
Comprehensive income (loss)	(518		)	(40,292		)	(17,977		)	(219,560		)
Basic income (loss) from continuing operations per share	$	(0.22	)	$	(0.89	)	$	(0.48	)	$	(5.25	)
Basic net income (loss) per share	$	(0.22	)	$	(0.89	)	$	(0.48	)	$	(5.25	)
Diluted income (loss) from continuing operations per share	$	(0.22	)	$	(0.89	)	$	(0.48	)	$	(5.25	)
Diluted net income (loss) per share	$	(0.22	)	$	(0.89	)	$	(0.48	)	$	(5.25	)



2017	First Quarter		Second Quarter			Third Quarter			Fourth Quarter
Net sales	$	157,555	$	157,947		$	148,156		$	156,135
Cost of sales (exclusive of depreciation and amortization)	114,480		114,514			111,272			118,814
Income (loss) from continuing operations	1,893		(26,374		)	(3,480		)	53,325
Income (loss) from discontinued operations, net of tax	5,518		5,236			129,441			(2,507		)
Net income (loss)	7,411		(21,138		)	125,961			50,818
Comprehensive income (loss)	12,516		(11,627		)	123,129			51,885
Basic income (loss) from continuing operations per share	$	0.07	$	(0.96	)	$	(0.13	)	$	1.93
Basic net income (loss) per share	$	0.27	$	(0.77	)	$	4.57		$	1.84
Diluted income (loss) from continuing operations per share	$	0.07	$	(0.96	)	$	(0.13	)	$	1.91
Diluted net income (loss) per share	$	0.27	$	(0.77	)	$	4.57		$	1.82

Subsequent Event	12 Months Ended
Subsequent Event	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Event	. Subsequent Event On February 8, 2019, the Company entered into a fixed-rate interest swap agreement with a notional amount of $700 million to manage the Company’s exposure to interest rate risk associated with our variable rate long-term debt.

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Nature of Business

Basis of Presentation

Principles of Consolidation

Use of Estimates in the Preparation of Financial Statements

Accounting Standards Recently Adopted

Accounting Standards Not Yet Adopted

Cash and Cash Equivalents

Cash and cash equivalents include cash and highly liquid investments with original maturities of three months or less.

Fair Value Measurements

Accounts Receivable and Allowance for Doubtful Accounts

Inventories

Property, Plant and Equipment

Goodwill and Other Indefinite Lived Intangible Assets

Impairment of Long-Lived Assets

Equity Method Investments

Income Taxes

Revenue Recognition

Share Based Compensation

Foreign Currency Translation

Net Income Per Common Share

Business Combinations

Examples of significant estimates used to value certain intangible assets acquired include but are not limited to:


•	sales volume, pricing and future cash flows of the business overall;


•	future expected cash flows from customer relationships, and other identifiable intangible assets, including future price levels, rates of increase in revenue and appropriate attrition rate;


•	the acquired company’s brand and competitive position, royalty rate quantum, as well as assumptions about the period of time the acquired brand will continue to benefit the combined company’s product portfolio; and


•	cost of capital, risk-adjusted discount rates, and income tax rates.

Discontinued Operations (Tables)

12 Months Ended

Dec. 31, 2018

Discontinued Operations and Disposal Groups [Abstract]

Summary of Discontinued Operations

The following table summarizes the major line items included in the results of operations of the discontinued operations.



	Year Ended December 31,
	2017 ⁽¹⁾			2016
Net sales	$	168,287		$	248,534
Cost of products sold (exclusive of depreciation and amortization shown separately below)	130,555			192,994
Selling, general and administrative expense	11,818			16,992
Depreciation and amortization	7,722			11,852
Loss on disposal of assets	—			27
Restructuring and integration expense	429			4,366
Income from operations	17,763			22,303
Interest expense	(181		)	(284		)
Other income (expense), net	(84		)	503
Income from discontinued operations before gain on disposal and provision for income taxes	17,498			22,522
Provision for income taxes on discontinued operations	(7,461		)	(6,369		)
Income from discontinued operations before gain on disposal	10,037			16,153
Gain on disposal of discontinued operations	213,503			—
Provision for income taxes on gain on disposal	(85,852		)	—
Income from discontinued operations, net of tax	$	137,688		$	16,153

_________________________________


(1)	Includes the results of operations of the PBC Business from January 1, 2017 to the sale completion date of August 17, 2017.

The following table presents the significant noncash items and cash paid for capital expenditures of discontinued operations for each period presented.



	Year Ended December 31,
	2017		2016
Depreciation and amortization	$	7,722	$	11,852
Acquisition of property, plant and equipment	$	7,316	$	11,926

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=84176398&loc=SL51724579-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84176398&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

+ Details

Acquisitions (Tables)

12 Months Ended

Dec. 31, 2018

Schedule of Business Acquisitions, by Acquisition

The following table summarizes the preliminary purchase price allocation for the Paragon Medical acquisition.



Fair value of assets acquired and liabilities assumed as of May 7, 2018	As Reported on June 30, 2018		Subsequent Adjustments to Fair Value			As Reported on December 31, 2018
Cash and cash equivalents	$	13,418	$	134		$	13,552
Accounts receivable	22,853		(721		)	22,132
Inventories	23,606		(400		)	23,206
Other current assets	937		734			1,671
Property, plant and equipment	69,322		(5,625		)	63,697
Intangible assets subject to amortization	164,200		(700		)	163,500
Other non-current assets	3,304		(129		)	3,175
Goodwill	157,421		4,399			161,820
Total assets acquired	$	455,061	$	(2,308	)	$	452,753
Current liabilities	$	16,767	$	234		$	17,001
Deferred tax liability	46,713		(2,442		)	44,271
Other non-current liabilities	620		—			620
Total liabilities assumed	$	64,100	$	(2,208	)	$	61,892
Net assets acquired	$	390,961	$	(100	)	$	390,861

Business Acquisition, Pro Forma Information

The provision for income taxes has also been adjusted for all periods, based upon the foregoing adjustments to historical results. The impact of adopting ASC 606 has been included based on an adoption date of January 1, 2018.



	Year Ended December 31,
	2018			2017
Pro forma net sales	$	825,891		$	760,772
Pro forma income (loss) from continuing operations	$	(252,268	)	$	3,227
Pro forma net income (loss)	$	(252,268	)	$	140,915
Basic income (loss) from continuing operations per share	$	(7.96	)	$	0.12
Diluted income (loss) from continuing operations per share	$	(7.96	)	$	0.12

Segment Information (Tables)

12 Months Ended

Dec. 31, 2018

Segment Reporting [Abstract]

Segment Information

The following table presents results of continuing operations for each reportable segment.



	Mobile Solutions			Power Solutions			Life Sciences		Corporate and Consolidations				Total
Year Ended December 31, 2018
Net sales	$	335,037		$	189,778		$	248,173	$	(2,331	)	(a)	$	770,657
Depreciation and amortization	$	26,217		$	14,753		$	28,091	$	2,067			$	71,128
Goodwill impairment	$	73,442		$	109,100		$	—	$	—			$	182,542
Income from operations	$	(54,103	)	$	(95,115	)	$	19,136	$	(48,806	)		$	(178,888	)
Interest expense													$	(61,243	)
Other													$	(20,903	)
Loss from continuing operations before benefit for income taxes and share of net income from joint venture													$	(261,034	)
Share of net income from joint venture	$	(14,390	)	—			—		—				$	(14,390	)
Expenditures for long-lived assets	$	36,660		$	6,459		$	14,645	$	6,272			$	64,036
Total assets	$	356,387		$	297,947		$	802,770	$	44,466		(b)	$	1,501,570
Year Ended December 31, 2017
Net sales	$	336,852		$	186,602		$	98,329	$	(1,990	)	(a)	$	619,793
Depreciation and amortization	$	24,491		$	14,657		$	12,088	$	1,170			$	52,406
Income from operations	$	34,405		$	23,440		$	13,271	$	(38,002	)		$	33,114
Interest expense													$	(52,085	)
Other													$	(39,902	)
Loss from continuing operations before benefit for income taxes and share of net income from joint venture													$	(58,873	)
Share of net income from joint venture	$	5,211		—			—		—				$	5,211
Expenditures for long-lived assets	$	24,056		$	5,443		$	—	$	6,907			$	36,406
Total assets	$	428,321		$	385,558		$	353,208	$	307,916		(b)	$	1,475,003
Year Ended December 31, 2016
Net sales	$	326,138		$	180,330		$	80,057	$	(1,571	)	(a)	$	584,954
Depreciation and amortization	$	22,189		$	15,604		$	12,501	$	427			$	50,721
Income from operations	$	29,490		$	24,060		$	9,840	$	(28,611	)		$	34,779
Interest expense													$	(62,870	)
Other													$	(2,775	)
Loss from continuing operations before benefit for income taxes and share of net income from joint venture													$	(30,866	)
Share of net income from joint venture	$	5,938		—			—		—				$	5,938
Expenditures for long-lived assets	$	23,077		$	3,125		$	2,227	$	3,465			$	31,894

_______________________________

(a) Includes eliminations of intersegment transactions which occur during the ordinary course of business.

(b) Total assets in Mobile Solutions includes $20.4 million and $39.8 million as of December 31, 2018 and 2017, respectively, related to the investment in our 49% owned joint venture (Note 10).



	Year Ended December 31,
	2018		2017
Net sales
Paragon Medical	$	116,998	$	—
NN Vandalia	30,668		6,682
Other	11,968		—

Income (loss) from operations
Paragon Medical	$	8,086	$	—
NN Vandalia	1,532		(458		)
Other	284		—

Summary of Sales to External Customers and Long-Lived Tangible Assets by Geographical Region

The following table summarizes long-lived tangible assets by geographical region.



	Property, Plant, and Equipment, Net As of December 31,
	2018		2017
United States	$	235,975	$	173,269
Europe	50,143		25,288
Asia	42,657		26,078
Mexico	7,647		7,544
S. America	24,606		27,101
All foreign countries	$	125,053	$	86,011
Total	$	361,028	$	259,280

Accounts Receivable and Sales Concentrations (Tables)

12 Months Ended

Dec. 31, 2018

Receivables [Abstract]

Summary of Accounts Receivables

Accounts receivable, net are comprised of the following amounts:



	As of December 31,
	2018		2017
Trade	$	135,260	$	110,165
Less—allowance for doubtful accounts	1,839		1,719
Accounts receivable, net	$	133,421	$	108,446

Summary of Activity in the Allowance for Doubtful Accounts

The following table presents activity in the allowance for doubtful accounts.



	Year Ended December 31,
	2018			2017			2016
Balance at beginning of year	$	1,719		$	1,069		$	1,055
Additions	754			648			153
Write-offs	(584		)	(101		)	(59		)
Currency impact	(50		)	103			(80		)
Balance at end of year	$	1,839		$	1,719		$	1,069

Inventories (Tables)

12 Months Ended

Dec. 31, 2018

Inventory Disclosure [Abstract]

Summary of Inventories

Inventories are comprised of the following amounts:



	As of December 31,
	2018		2017
Raw materials	$	52,930	$	37,337
Work in process	42,578		27,669
Finished goods	27,107		17,611
Inventories	$	122,615	$	82,617

Property, Plant and Equipment (Tables)

12 Months Ended

Dec. 31, 2018

Property, Plant and Equipment [Abstract]

Summary of Property, Plant and Equipment

Property, plant and equipment are comprised of the following amounts:



	As of December 31,
	2018		2017
Land and buildings	$	69,455	$	54,833
Machinery and equipment	401,729		302,470
Construction in progress	35,122		14,346
Total	506,306		371,649
Less—accumulated depreciation	145,278		112,369
Property, plant and equipment, net	$	361,028	$	259,280

Goodwill (Tables)

12 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Changes in Carrying Amount of Goodwill

The following table shows the gross carrying amount of goodwill and accumulated impairment charges as of December 31, 2018 and 2017.



	December 31, 2018							December 31, 2017
	Gross Carrying Amount		Accumulated Impairment Charges			Net Book Value		Gross Carrying Amount		Accumulated Impairment Charges			Net Book Value
Mobile Solutions	$	74,147	$	(74,147	)	$	—	$	74,147	$	—		$	74,147
Power Solutions	205,405		(110,900		)	94,505		204,481		(1,800		)	202,681
Life Sciences	344,947		—			344,947		177,784		—			177,784
Total goodwill	$	624,499	$	(185,047	)	$	439,452	$	456,412	$	(1,800	)	$	454,612

The following table shows changes in the carrying amount of goodwill for the years ended December 31, 2018, and 2017.



	Mobile Solutions			Power Solutions			Life Sciences			Total
Balance as of December 31, 2016	$	73,263		$	201,934		$	168,332		$	443,529
Currency impact	884			747			—			1,631
Goodwill acquired in acquisitions	—			—			9,452			9,452
Balance as of December 31, 2017	74,147			202,681			177,784			454,612
Currency impact and other	(705		)	(1,882		)	(3,118		)	(5,705		)
Goodwill acquired in acquisitions	—			2,657			165,288			167,945
Impairments	(73,442		)	(109,100		)	—			(182,542		)
Measurement period adjustments	—			149			4,993			5,142
Balance as of December 31, 2018	$	—		$	94,505		$	344,947		$	439,452

Intangible Assets, Net (Tables)

12 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Acquired Finite-Lived Intangible Assets by Major Class



	Gross Carrying Value as of Acquisition Date		Weighted Average Estimated Useful Life in Years
Customer relationships	$	146,800	20
Trademark and trade name	14,700		29
Other	9,613		1
Total intangible assets acquired in current year	$	171,113	19

Summary of Carrying Amount of Intangible Assets by Segment and by Major Asset Class

The following table shows changes in the carrying amount of intangible assets, net.



	Mobile Solutions			Power Solutions			Life Sciences			Total
Balance as of December 31, 2016	$	42,928		$	115,928		$	95,407		$	254,263
Amortization	(3,481		)	(10,898		)	(9,081		)	(23,460		)
Currency impacts	(1		)	—			—			(1		)
Intangible assets acquired in acquisition	—			—			6,900			6,900
Balance as of December 31, 2017	$	39,446		$	105,030		$	93,226		$	237,702
Amortization	(3,540		)	(10,939		)	(18,074		)	(32,553		)
Currency impacts	(14		)	—			—			(14		)
Intangible assets acquired in acquisitions	—			1,900			169,213			171,113
Measurement period adjustments	—			—			—			—
Balance as of December 31, 2018	$	35,892		$	95,991		$	244,365		$	376,248

The following table shows the cost and accumulated amortization of our intangible assets as of December 31, 2018 and 2017.



		December 31, 2018							December 31, 2017
	Estimated Useful Life in Years	Gross Carrying Value as of Acquisition Date		Accumulated Amortization			Net Carrying Value		Gross Carrying Value as of Acquisition Date		Accumulated Amortization			Net Carrying Value
Customer relationships	12 - 20	$	428,830	$	(75,581	)	$	353,249	$	282,030	$	(52,408	)	$	229,622
Trademark and trade name	8 - 30	25,100		(4,085		)	21,015		10,460		(2,703		)	7,757
Other	1 - 5	10,641		(8,657		)	1,984		8,740		(8,417		)	323
Total identified intangible assets		$	464,571	$	(88,323	)	$	376,248	$	301,230	$	(63,528	)	$	237,702

Summary of Estimated Amortization Expense

The following table summarizes estimated future amortization expense for the next five years and thereafter.




Year Ending December 31,
2019	$	47,009
2020	45,357
2021	41,415
2022	38,464
2023	36,625
Thereafter	167,378
Total	$	376,248

Investment in Joint Venture (Tables)

12 Months Ended

Dec. 31, 2018

Equity Method Investments and Joint Ventures [Abstract]

Summarized Activity Related to Investment in Joint Venture

The following table summarizes activity related to our investment in the JV.



Balance as of December 31, 2017	$	39,822
Share of earnings	2,543
Dividends declared and paid by joint venture	(2,842		)
Accretion of basis difference from purchase accounting	(343		)
Foreign currency translation loss	(2,227		)
Impairment	(16,589		)
Balance as of December 31, 2018	$	20,364

Summarized Income Statement Information of Unconsolidated Joint Venture

The following tables show selected financial data of the JV.



	Year Ended December 31,
	2018		2017		2016
Net sales	$	69,901	$	74,805	$	65,756
Cost of sales	57,596		57,514		44,530
Income from operations	6,853		13,659		16,268
Net income	4,646		11,442		13,702

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Loss from Continuing Operations Before Benefit for Income Taxes

Loss from continuing operations before benefit for income taxes was as follows:



	Year Ended December 31,
	2018			2017			2016
Loss from continuing operations before benefit for income taxes and share of net income from joint venture
United States	$	(263,499	)	$	(71,603	)	$	(39,160	)
Foreign	2,465			12,730			8,294
Total	$	(261,034	)	$	(58,873	)	$	(30,866	)

Income Tax Benefit

Total income tax benefit was as follows:



	Year Ended December 31,
	2018			2017			2016
Current taxes:
U.S. Federal	$	8,150		$	(47,916	)	$	(2,595	)
State	584			(12,226		)	679
Foreign	3,086			4,310			2,004
Total current tax expense (benefit)	11,820			(55,832		)	88
Deferred taxes:
U.S. Federal	$	(16,129	)	$	(25,017	)	$	(9,679	)
State	(780		)	3,009			(6,406		)
Deferred tax valuation allowance	(3,565		)	710			1,882
Foreign	(2,303		)	(1,896		)	(1,323		)
Total deferred tax benefit	(22,777		)	(23,194		)	(15,526		)
Total income tax benefit	$	(10,957	)	$	(79,026	)	$	(15,438	)

Reconciliation of Income Taxes Based on U.S. Federal Statutory Rate

A reconciliation of income taxes based on the U.S. federal statutory income tax rate is summarized as follows:



	Year Ended December 31,
	2018		2017		2016
U.S federal statutory income tax rate	21.0	%	35.0	%	34.0	%
Change in valuation allowance	(0.9	)%	(1.2	)%	(6.1	)%
Foreign tax credits, exclusive of tax reform	—	%	(13.8	)%	8.2	%
State taxes, net of federal taxes, exclusive of tax reform	0.4	%	9.1	%	5.7	%
Non-U.S. earnings taxed at different rates	1.2	%	1.7	%	4.8	%
Non-deductible mergers and acquisitions costs	(0.2	)%	—	%	—	%
GILTI	(0.3	)%	—	%	—	%
Goodwill impairment	(15.5	)%	—	%	—	%
R&D Tax credit	0.3	%	0.3	%	0.9	%
Change in uncertain tax positions	0.3	%	(0.4	)%	3.2	%
Impact of Tax Reform
Toll Charge, net of foreign tax credit	0.6	%	(11.5	)%	—	%
Remeasurement of deferred taxes pursuant to tax reform	(0.9	)%	65.6	%	—	%
Tax Reform impact on divestiture of business segment	—	%	33.9	%	—	%
Section 199/Domestic Production Deduction	—	%	0.8	%	—	%
Divestiture of Business Segment, exclusive of tax reform	(0.9	)%	13.6	%	—	%
Return to provision	(0.8	)%	—	%	—	%
Prior period revisions	—	%	0.5	%	4.2	%
Foreign JV net income	—	%	—	%	(4.1	)%
Other adjustments, net	(0.1	)%	0.6	%	(0.8	)%
Effective tax rate	4.2	%	134.2	%	50.0	%

Principal Components of Deferred Tax Assets and Liabilities

The principal components of the deferred tax assets and liabilities are as follows:



	As of December 31,
	2018			2017
Deferred income tax liabilities:
Tax in excess of book depreciation	$	37,425		$	34,143
Goodwill	—			58
Intangible assets	80,623			50,688
Other deferred tax liabilities	794			389
Total deferred income tax liabilities	118,842			85,278
Deferred income tax assets:
Interest expense limitation	9,968			—
Goodwill	1,441			2,067
Inventories	2,745			2,248
Pension/Personnel accruals	1,317			1,596
Net operating loss carry forwards	9,321			6,950
Foreign tax credits	5,345			—
Credit carry forwards	4,130			3,427
Accruals and reserves	1,531			2,015
Other deferred tax assets	4,022			3,019
Deferred income tax assets before Valuation Allowance	39,820			21,322
Valuation allowance on deferred tax assets	(14,460		)	(7,608		)
Total deferred income tax assets	25,360			13,714
Net deferred income tax liabilities ⁽¹⁾	$	93,482		$	71,564

________________________


(1)	In accordance with the Tax Act, our ending domestic deferred balances have been remeasured to 21% for the year ended December 31, 2017.

Summary of Activity in Total Valuation Allowances

The following table summarizes our total valuation allowances:



	Year Ended December 31,
	2018		2017		2016
Balance at beginning of year	$	7,608	$	4,090	$	2,376
Additions	6,852		3,518		1,882
Recoveries	—		—		(168		)
Balance at end of year	$	14,460	$	7,608	$	4,090

Summary of Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits, Excluding Interest and Penalties

A reconciliation of the beginning and ending amounts of unrecognized tax benefits, excluding interest and penalties, is as follows:



	Year Ended December 31,
	2018			2017			2016
Balance at beginning of year	$	5,655		$	4,741		$	5,724
Additions for tax positions of prior years	304			1,404			179
Reductions for tax positions of prior years	(1,350		)	(490		)	(1,162		)
Balance at end of year	$	4,609		$	5,655		$	4,741

Debt (Tables)

12 Months Ended

Dec. 31, 2018

Debt Disclosure [Abstract]

Summary of Debt

The following table presents outstanding debt balances as of December 31, 2018 and 2017.



	As of December 31,
	2018		2017
Senior Secured Term Loan	$	532,063	$	534,250
Incremental Term Loan	279,000		291,000
Senior Secured Revolver	38,720		—
International lines of credit and other loans	9,810		3,315
Total principal	859,593		828,565
Less—current maturities of long-term debt	31,280		17,283
Principal, net of current portion	828,313		811,282
Less—unamortized debt issuance costs	16,842		20,477
Long-term debt, net of current portion	$	811,471	$	790,805

Aggregate Maturities of Long-Term Debt

The following table lists aggregate maturities of long-term debt for the next five years and thereafter.



Year Ending December 31,	Aggregate Maturities Principal Amounts
2019	$	31,280
2020	50,097
2021	261,094
2022	515,157
2023	344
Thereafter	1,621

Total outstanding principal	$	859,593

Restructuring and Integration (Tables)

12 Months Ended

Dec. 31, 2018

Restructuring and Related Activities [Abstract]

Summary of Restructuring and Integration Charges and Reserve Activity

The following table summarizes restructuring and integration charges for the years ended December 31, 2018, 2017, and 2016.



	Mobile Solutions		Power Solutions		Life Sciences		Corporate and Consolidations		Total
Year Ended December 31, 2018
Severance and other employee costs	$	—	$	—	$	1,336	$	728	$	2,064
Site closure and other associated costs	63		—		—		—		63
Total	$	63	$	—	$	1,336	$	728	$	2,127
Year Ended December 31, 2017
Severance and other employee costs	$	17	$	—	$	—	$	—	$	17
Site closure and other associated costs	369		—		—		—		369
Total	$	386	$	—	$	—	$	—	$	386
Year Ended December 31, 2016
Severance and other employee costs	$	851	$	455	$	381	$	—	$	1,687
Site closure and other associated costs	3,488		263		220		—		3,971
Total	$	4,339	$	718	$	601	$	—	$	5,658

The following tables summarize restructuring and integration reserve activity for the years ended December 31, 2018, 2017, and 2016.



	Reserve Balance as of December 31, 2017		Charges		Non-cash Adjustments			Cash Reductions			Reserve Balance as of December 31, 2018
Severance and other employee costs	$	—	$	2,064	$	—		$	(942	)	$	1,122
Site closure and other associated costs	1,099		63		(56		)	(1,082		)	24
Total	$	1,099	$	2,127	$	(56	)	$	(2,024	)	$	1,146

	Reserve Balance as of December 31, 2016		Charges		Non-cash Adjustments			Cash Reductions			Reserve Balance as of December 31, 2017
Severance and other employee costs	$	1,000	$	17	$	(164	)	$	(853	)	$	—
Site closure and other associated costs	1,625		369		—			(895		)	1,099
Total	$	2,625	$	386	$	(164	)	$	(1,748	)	$	1,099

	Reserve Balance as of December 31, 2015		Charges		Non-cash Adjustments			Cash Reductions			Reserve Balance as of December 31, 2016
Severance and other employee costs	$	887	$	1,687	$	(278	)	$	(1,296	)	$	1,000
Site closure and other associated costs	1,845		3,971		(2,142		)	(2,049		)	1,625
Total	$	2,732	$	5,658	$	(2,420	)	$	(3,345	)	$	2,625

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Schedule by Year of Future Minimum Lease Payments

The following table summarizes future minimum lease payments as of December 31, 2018, under operating leases that have initial or remaining non-cancelable lease terms in excess of one year.



Year Ending December 31,	Minimum Rental Commitments
2019	$	13,337
2020	11,515
2021	10,557
2022	10,293
2023	8,752
Thereafter	53,945

Total minimum payments	$	108,399

Revenue from Contracts with Customers (Tables)

12 Months Ended

Dec. 31, 2018

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

The following tables summarize sales to external customers by operating segment for the years ended December 31, 2018, 2017, and 2016.



	Year Ended December 31, 2018
	Mobile Solutions		Power Solutions		Life Sciences		Intersegment Sales Eliminations			Total
United States	$	187,178	$	157,357	$	206,776	$	(2,331	)	$	548,980
China	43,610		5,537		6,130		—			55,277
Mexico	27,053		12,254		191		—			39,498
Brazil	35,314		215		29		—			35,558
Germany	5,652		26		19,870		—			25,548
Switzerland	5,006		54		6,446		—			11,506
Poland	7,010		13		8		—			7,031
Italy	5,558		221		317		—			6,096
Czech Republic	6,131		47		—		—			6,178
Netherlands	—		3,290		—		—			3,290
Other	12,525		10,764		8,406		—			31,695
Total net sales	$	335,037	$	189,778	$	248,173	$	(2,331	)	$	770,657



	Year Ended December 31, 2017
	Mobile Solutions		Power Solutions		Life Sciences		Intersegment Sales Eliminations			Total
United States	$	190,828	$	152,938	$	96,062	$	(1,990	)	$	437,838
China	45,503		6,481		267		—			52,251
Mexico	26,639		14,220		78		—			40,937
Brazil	35,425		185		—		—			35,610
Germany	5,502		11		35		—			5,548
Switzerland	5,450		—		—		—			5,450
Poland	5,183		—		—		—			5,183
Italy	5,347		334		—		—			5,681
Czech Republic	—		—		—		—			—
Netherlands	—		2,817		—		—			2,817
Other	16,975		9,616		1,887		—			28,478
Total net sales	$	336,852	$	186,602	$	98,329	$	(1,990	)	$	619,793



	Year Ended December 31, 2016
	Mobile Solutions		Power Solutions		Life Sciences		Intersegment Sales Eliminations			Total
United States	$	196,217	$	134,564	$	78,707	$	(1,571	)	$	407,917
China	44,579		8,131		403		—			53,113
Mexico	24,919		20,944		—		—			45,863
Brazil	23,801		458		—		—			24,259
Germany	4,497		8		35		—			4,540
Switzerland	—		—		—		—			—
Poland	—		—		—		—			—
Italy	5,027		322		—		—			5,349
Czech Republic	—		—		—		—			—
Netherlands	—		1,882		—		—			1,882
Other	27,098		14,021		912		—			42,031
Total net sales	$	326,138	$	180,330	$	80,057	$	(1,571	)	$	584,954

Contract with Customer, Asset and Liability

The following table provides information about contract liabilities from contracts with customers.



	Deferred Revenue
Balance at January 1, 2018	$	2,124
Balance at December 31, 2018	$	2,974

Schedule of New Accounting Pronouncements and Changes in Accounting Principles



	Year Ended December 31, 2018
	As Reported			Balances Without Adoption of ASC 606			Effect of Change
Net sales	$	770,657		$	770,654		$	3
Cost of sales	588,205			588,202			3
Income (loss) from operations	(178,888		)	(178,888		)	—



	As of December 31, 2018
	As Reported		Balances Without Adoption of ASC 606		Effect of Change
Accounts receivable, net	$	133,421	$	132,810	$	611
Inventories	122,615		122,988		(373		)

Share-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Components of Share-Based Compensation Expense by Type of Award

The following table lists the components of share-based compensation expense by type of award.



	Year Ended December 31,
	2018			2017		2016
Stock options	$	678		$	1,078	$	687
Restricted stock	1,630			1,968		2,061
Performance share units	2,076			2,450		1,187
Change in estimate of performance share vesting ⁽¹⁾	(1,968		)	—		—
Share-based compensation expense	$	2,416		$	5,496	$	3,935

Weighted Average Assumptions Relevant to Determining the Fair Value at the Dates of Grant and Stock Option Modification

The following table shows the weighted average assumptions relevant to determining the fair value of stock options granted in each year.



	2018		2017		2016
Expected term	6 years		6 years		6 years
Average risk-free interest rate	2.66	%	2.03	%	1.43	%
Expected dividend yield	1.15	%	1.16	%	2.48	%
Expected volatility	47.69	%	56.56	%	59.23	%
Expected forfeiture rate	4.00	%	3.00	%	3.00	%

Reconciliation of Option Activity

The following table summarizes stock option activity for the year ended December 31, 2018.



	Number of Options (in thousands)		Weighted- Average Exercise Price (per share)		Weighted- Average Remaining Contractual Term (years)	Aggregate Intrinsic Value
Outstanding at January 1, 2018	746		$	14.33
Granted	58		24.47
Exercised	(27	)	10.15			$	477
Forfeited or expired	(6	)	22.39
Outstanding at December 31, 2018	771		$	15.17	5.6	$	—	⁽¹⁾
Exercisable at December 31, 2018	625		$	13.63	4.9	$	—	⁽¹⁾


(1)	The aggregate intrinsic value is the sum of intrinsic values for each exercisable individual option grant. The intrinsic value is the amount by which the closing market price of our stock at December 31, 2018, was greater than the exercise price of any individual option grant.

Reconciliation of Restricted Stock Option Activity

The following table summarizes unvested restricted stock award activity for the year ended December 31, 2018.



	Number of Unvested Restricted Shares (in thousands)		Weighted Average Grant Date Fair Value
Unvested at January 1, 2018	152		$	19.21
Granted	87		24.55
Vested	(93	)	19.69
Forfeited	—		—
Unvested at December 31, 2018	146		$	22.07

Schedule of Performance Based Awards Goals with Respect to TSR and ROIC

The following table presents the goals with respect to TSR Awards and ROIC Awards granted in 2018, 2017, and 2016.



ROIC Awards:	Threshold Performance (35% of Shares)		Target Performance (100% of Shares)		Maximum Performance (150% of Shares)
2018 grants	15.5	%	18.0	%	19.5	%
2017 grants	15.0	%	17.5	%	20.0	%
2016 grants	15.5	%	18.0	%	20.5	%

Schedule of Number of Awards Granted and Grant Date Fair Value of Each Award in Periods

The following table presents the number of awards granted and the grant date fair value of each award in the periods presented.



	TSR Awards			ROIC Awards
Award Year	Number of Shares (in thousands)	Grant Date Fair Value (per share)		Number of Shares (in thousands)	Grant Date Fair Value (per share)
2018	55	$	24.65	55	$	24.55
2017	46	$	29.84	53	$	24.20
2016	101	$	9.38	101	$	11.31

Summary of Status of Unvested PSU Awards

The following table summarizes changes in unvested PSUs during the year ended December 31, 2018, and changes during the year then ended.



	Nonvested TSR Awards				Nonvested ROIC Awards
	Number of Shares (in thousands)		Weighted Average Grant Date Fair Value		Number of Shares (in thousands)		Weighted Average Grant Date Fair Value
Nonvested at January 1, 2018	130		$	16.60	136		$	16.27
Granted	55		24.65		55		24.55
Vested	—		—		—		—
Expired	(78	)	9.38		(77	)	11.31
Forfeited	(13	)	14.50		(14	)	14.86
Nonvested at December 31, 2018	94		$	26.84	100		$	24.39

Net Income (Loss) Per Share (Tables)

12 Months Ended

Dec. 31, 2018

Earnings Per Share [Abstract]

Summary of Net Income (Loss) Per Share

The following table summarizes the computation of basic and diluted net income (loss) per share.



	Year Ended December 31,
	2018			2017		2016
Income (loss) from continuing operations	$	(264,467	)	$	25,364	$	(9,490	)
Income from discontinued operations, net of tax	—			137,688		16,153
Net income (loss)	$	(264,467	)	$	163,052	$	6,663

Weighted average shares outstanding	31,678			27,433		27,016
Effect of dilutive stock options	—			322		—
Diluted shares outstanding	31,678			27,755		27,016

Basic income (loss) from continuing operations per share	$	(8.35	)	$	0.92	$	(0.35	)
Basic income from discontinued operations per share	—			5.02		0.60
Basic net income (loss) per share	$	(8.35	)	$	5.94	$	0.25

Diluted income (loss) from continuing operations per share	$	(8.35	)	$	0.91	$	(0.35	)
Diluted income from discontinued operations per share	—			4.96		0.60
Diluted net income (loss) per share	$	(8.35	)	$	5.87	$	0.25
Cash dividends declared per common share	$	0.28		$	0.28	$	0.28

Quarterly Results of Operations (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2018

Quarterly Financial Information Disclosure [Abstract]

Summary of Unaudited Quarterly Results of Operations

The following tables summarize the quarterly results of operations for the years ended December 31, 2018 and 2017.



2018	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
Net sales	$	169,148		$	196,349		$	205,683		$	199,477
Cost of sales (exclusive of depreciation and amortization)	126,444			148,640			156,408			156,713
Income (loss) from continuing operations	(5,983		)	(24,511		)	(13,784		)	(220,189		)
Net income (loss)	(5,983		)	(24,511		)	(13,784		)	(220,189		)
Comprehensive income (loss)	(518		)	(40,292		)	(17,977		)	(219,560		)
Basic income (loss) from continuing operations per share	$	(0.22	)	$	(0.89	)	$	(0.48	)	$	(5.25	)
Basic net income (loss) per share	$	(0.22	)	$	(0.89	)	$	(0.48	)	$	(5.25	)
Diluted income (loss) from continuing operations per share	$	(0.22	)	$	(0.89	)	$	(0.48	)	$	(5.25	)
Diluted net income (loss) per share	$	(0.22	)	$	(0.89	)	$	(0.48	)	$	(5.25	)



2017	First Quarter		Second Quarter			Third Quarter			Fourth Quarter
Net sales	$	157,555	$	157,947		$	148,156		$	156,135
Cost of sales (exclusive of depreciation and amortization)	114,480		114,514			111,272			118,814
Income (loss) from continuing operations	1,893		(26,374		)	(3,480		)	53,325
Income (loss) from discontinued operations, net of tax	5,518		5,236			129,441			(2,507		)
Net income (loss)	7,411		(21,138		)	125,961			50,818
Comprehensive income (loss)	12,516		(11,627		)	123,129			51,885
Basic income (loss) from continuing operations per share	$	0.07	$	(0.96	)	$	(0.13	)	$	1.93
Basic net income (loss) per share	$	0.27	$	(0.77	)	$	4.57		$	1.84
Diluted income (loss) from continuing operations per share	$	0.07	$	(0.96	)	$	(0.13	)	$	1.91
Diluted net income (loss) per share	$	0.27	$	(0.77	)	$	4.57		$	1.82

Significant Accounting Policies - Additional Information (Detail) $ in Thousands	1 Months Ended	12 Months Ended
	Apr. 30, 2017 USD ($)	Dec. 31, 2018 USD ($) Facility	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Jan. 01, 2019 USD ($)	Jan. 01, 2018 USD ($)
Significant Accounting Policies [Line Items]
Number of manufacturing facilities \| Facility		51
Net profit change on contracts		$ (62,046)	$ 211,080
Cash paid for debt prepayment	$ 31,600
Goodwill impairment		$ 182,542	0	$ 0
Maturity period of highly liquid investments		three months or less
Goodwill impairment		$ 182,542	$ 0	$ 0
Land and buildings \| Minimum
Significant Accounting Policies [Line Items]
Estimated useful lives		15 years
Land and buildings \| Maximum
Significant Accounting Policies [Line Items]
Estimated useful lives		40 years
Machinery and equipment \| Minimum
Significant Accounting Policies [Line Items]
Estimated useful lives		3 years
Machinery and equipment \| Maximum
Significant Accounting Policies [Line Items]
Estimated useful lives		12 years
Joint Venture
Significant Accounting Policies [Line Items]
Investment in joint venture		49.00%
Accounting Standards Update 2014-09
Significant Accounting Policies [Line Items]
Net profit change on contracts						$ 100
Subsequent Event \| Scenario, Forecast \| Accounting Standards Update 2016-02 \| Minimum
Significant Accounting Policies [Line Items]
Operating lease, right-of-use asset					$ 65,000
Operating lease, liability					65,000
Subsequent Event \| Scenario, Forecast \| Accounting Standards Update 2016-02 \| Maximum
Significant Accounting Policies [Line Items]
Operating lease, right-of-use asset					95,000
Operating lease, liability					$ 95,000

Discontinued Operations - Additional Information (Detail) - USD ($) $ in Thousands		12 Months Ended
	Aug. 17, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of business		$ 838	$ 371,436	$ 0
Precision Bearing Components Group
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on cumulative foreign currency translation	$ 9,300
Discontinued Operations, Disposed of by Sale \| PBC Business \| Precision Bearing Components Group
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of business	387,600
Receivables	$ 800
Estimated after-tax gain on sale			$ 127,700

Discontinued Operations - Summary of Major Line Items Included in Results of Operations of Discontinued Operations (Detail) - USD ($) $ in Thousands	3 Months Ended				12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income from discontinued operations, net of tax	$ (2,507)	$ 129,441	$ 5,236	$ 5,518	$ 0	$ 137,688	$ 16,153
PBC Business \| Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net sales						168,287	248,534
Cost of products sold (exclusive of depreciation and amortization shown separately below)						130,555	192,994
Selling, general and administrative expense						11,818	16,992
Depreciation and amortization						7,722	11,852
Loss on disposal of assets						0	27
Restructuring and integration expense						429	4,366
Income from operations						17,763	22,303
Interest expense						(181)	(284)
Other income (expense), net						(84)	503
Income from discontinued operations before gain on disposal and provision for income taxes						17,498	22,522
Provision for income taxes on discontinued operations						(7,461)	(6,369)
Income from discontinued operations before gain on disposal						10,037	16,153
Gain on disposal of discontinued operations						213,503	0
Provision for income taxes on gain on disposal						(85,852)	0
Income from discontinued operations, net of tax						$ 137,688	$ 16,153

Discontinued Operations - Summary of Significant Noncash Items and Cash Paid for Capital Expenditures of Discontinued Operations (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Discontinued Operation, Alternative Cash Flow Information [Abstract]
Depreciation and amortization	$ 0	$ 7,722	$ 11,852
Acquisition of property, plant and equipment		$ 7,316	$ 11,926

Acquisitions - Additional Information (Detail) - USD ($)				3 Months Ended								12 Months Ended
	Dec. 31, 2018	May 07, 2018	Oct. 02, 2017	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Aug. 09, 2018	Feb. 22, 2018
Business Acquisition [Line Items]
Contract base price		$ 375,000,000
Acquisition related costs												$ 5,871,000	$ 344,000	$ 0
Financing costs												12,900,000
Revenues				$ 199,477,000	$ 205,683,000	$ 196,349,000	$ 169,148,000	$ 156,135,000	$ 148,156,000	$ 157,947,000	$ 157,555,000	770,657,000	619,793,000	584,954,000
Sales revenue												770,657,000	619,793,000	584,954,000
Income (loss) from operations												(178,888,000)	33,114,000	34,779,000
Goodwill	$ 439,452,000			439,452,000				$ 454,612,000				439,452,000	454,612,000	$ 443,529,000
Paragon Medical
Business Acquisition [Line Items]
Acquisition percentage		100.00%
Cash payment to acquire business	390,900,000
Cash and cash equivalents	13,552,000			13,552,000		13,418,000						13,552,000
Working capital adjustment												1,400,000
Finite-lived intangibles after post acquisition amortization	155,300,000			155,300,000								155,300,000
Acquired goodwill after post acquisition currency impact	158,700,000			158,700,000								158,700,000
Goodwill, expected tax deductible amount	2,800,000			2,800,000								2,800,000
Acquisition related costs												5,400,000
Revenues												116,998,000	0
Income (loss) from operations												8,086,000	0
Goodwill	161,820,000			161,820,000		$ 157,421,000						161,820,000
NN Vandalia
Business Acquisition [Line Items]
Acquisition percentage			100.00%
Revenues												30,668,000	6,682,000
Income (loss) from operations												1,532,000
Series of Individually Immaterial Business Acquisitions
Business Acquisition [Line Items]
Cash payment to acquire business			$ 38,700,000									22,000,000
Acquisition related costs												500,000	$ 300,000
Bridgemedica, LLC
Business Acquisition [Line Items]
Acquisition percentage																100.00%
Goodwill	8,000,000			8,000,000								8,000,000
Southern California Technical Arts, Inc.
Business Acquisition [Line Items]
Acquisition percentage															100.00%
Goodwill	$ 2,800,000			$ 2,800,000								$ 2,800,000

Acquisitions - Purchase Price Allocation (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Property, plant and equipment	$ 66,000	$ 66,000		$ 14,000
Intangible assets subject to amortization	171,113	171,113		6,900
Goodwill	439,452	439,452		$ 454,612	$ 443,529
Measurement period adjustments		5,142
Paragon Medical
Business Acquisition [Line Items]
Cash and cash equivalents	13,552	13,552	$ 13,418
Cash and cash equivalents, adjustment	134
Accounts receivable	22,132	22,132	22,853
Accounts receivable, adjustment	(721)
Inventories	23,206	23,206	23,606
Inventories, adjustment	(400)
Other current assets	1,671	1,671	937
Other current assets, adjustment	734
Property, plant and equipment	63,697	63,697	69,322
Property, plant, and equipment, adjustment	(5,625)
Intangible assets subject to amortization	163,500	163,500	164,200
Intangibles assets subject to amortization, adjustment	(700)
Other non-current assets	3,175	3,175	3,304
Other noncurrent assets, adjustment	(129)
Goodwill	161,820	161,820	157,421
Measurement period adjustments	4,399
Total assets acquired	452,753	452,753	455,061
Total assets acquired, adjustment	(2,308)
Current liabilities	17,001	17,001	16,767
Current liabilities, adjustment	234
Deferred tax liability	44,271	44,271	46,713
Deferred tax liabilities, adjustment	(2,442)
Other non-current liabilities	620	620	620
Other noncurrent liabilities, adjustment	0
Total liabilities assumed	61,892	61,892	64,100
Total liabilities assumed, adjustment	(2,208)
Net assets acquired, adjustment	(100)
Net assets acquired	$ 390,861	$ 390,861	$ 390,961

Acquistions - Pro Forma Financial Information (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Business Combinations [Abstract]
Pro forma net sales	$ 825,891	$ 760,772
Pro forma income (loss) from continuing operations	(252,268)	3,227
Pro forma net income (loss)	$ (252,268)	$ 140,915
Basic income (loss) from continuing operations per share (in us dollars per share)	$ (7.96)	$ 0.12
Diluted income (loss) from continuing operations per share (in us dollars per share)	$ (7.96)	$ 0.12
Costs expensed not considered ongoing		$ 15,000

Acquisitions - Consolidated Results of Operations (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Business Combinations [Abstract]
Net sales									$ 825,891	$ 760,772
Income (loss) from continuing operations									(252,268)	3,227
Revenues	$ 199,477	$ 205,683	$ 196,349	$ 169,148	$ 156,135	$ 148,156	$ 157,947	$ 157,555	770,657	619,793	$ 584,954
Income (loss) from continuing operations	$ (220,189)	$ (13,784)	$ (24,511)	$ (5,983)	$ 53,325	$ (3,480)	$ (26,374)	$ 1,893	$ (264,467)	$ 25,364	$ (9,490)

Segment Information - Segment Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Segment Reporting Information [Line Items]
Net sales	$ 770,657	$ 619,793	$ 584,954
Depreciation and amortization	71,128	52,406	50,721
Goodwill impairment	182,542	0	0
Income from operations	(178,888)	33,114	34,779
Interest expense	(61,243)	(52,085)	(62,870)
Other	(20,903)	(39,902)	(2,775)
Loss from continuing operations before benefit for income taxes and share of net income from joint venture	(261,034)	(58,873)	(30,866)
Share of net income (loss) from joint venture	(14,390)	5,211	5,938
Expenditures for long-lived assets	64,036	36,406	31,894
Total assets	1,501,570	1,475,003
Corporate And Eliminations
Segment Reporting Information [Line Items]
Net sales	(2,331)	(1,990)	(1,571)
Depreciation and amortization	2,067	1,170	427
Goodwill impairment	0
Income from operations	(48,806)	(38,002)	(28,611)
Share of net income (loss) from joint venture	0	0	0
Expenditures for long-lived assets	6,272	6,907	3,465
Total assets	44,466	307,916
Mobile Solutions
Segment Reporting Information [Line Items]
Goodwill impairment	73,442
Mobile Solutions \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	335,037	336,852	326,138
Depreciation and amortization	26,217	24,491	22,189
Goodwill impairment	73,442
Income from operations	(54,103)	34,405	29,490
Share of net income (loss) from joint venture	(14,390)	5,211	5,938
Expenditures for long-lived assets	36,660	24,056	23,077
Total assets	356,387	428,321
Power Solutions
Segment Reporting Information [Line Items]
Goodwill impairment	109,100
Power Solutions \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	189,778	186,602	180,330
Depreciation and amortization	14,753	14,657	15,604
Goodwill impairment	109,100
Income from operations	(95,115)	23,440	24,060
Share of net income (loss) from joint venture	0	0	0
Expenditures for long-lived assets	6,459	5,443	3,125
Total assets	297,947	385,558
Life Sciences
Segment Reporting Information [Line Items]
Goodwill impairment	0
Life Sciences \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	248,173	98,329	80,057
Depreciation and amortization	28,091	12,088	12,501
Goodwill impairment	0
Income from operations	19,136	13,271	9,840
Share of net income (loss) from joint venture	0	0	0
Expenditures for long-lived assets	14,645	0	$ 2,227
Total assets	$ 802,770	353,208
Wuxi Weifu Autocam Precision Machinery Company, Ltd.
Segment Reporting Information [Line Items]
Investment in joint venture	49.00%
Wuxi Weifu Autocam Precision Machinery Company, Ltd. \| Mobile Solutions \| Operating Segments
Segment Reporting Information [Line Items]
Total assets	$ 20,400	$ 39,800

Segment Information - Summary of Net Sale and Income (Loss) from Operations (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Segment Reporting Information [Line Items]
Net sales	$ 199,477	$ 205,683	$ 196,349	$ 169,148	$ 156,135	$ 148,156	$ 157,947	$ 157,555	$ 770,657	$ 619,793	$ 584,954
Income (loss) from operations									(178,888)	33,114	34,779
Income (loss) from continuing operations	$ (220,189)	$ (13,784)	$ (24,511)	$ (5,983)	$ 53,325	$ (3,480)	$ (26,374)	$ 1,893	(264,467)	25,364	$ (9,490)
Paragon Medical
Segment Reporting Information [Line Items]
Net sales									116,998	0
Income (loss) from operations									8,086	0
NN Vandalia
Segment Reporting Information [Line Items]
Net sales									30,668	6,682
Income (loss) from operations									1,532
Income (loss) from continuing operations										(458)
Other
Segment Reporting Information [Line Items]
Net sales									11,968	0
Income (loss) from operations									$ 284	$ 0

Segment Information - Summary of Sales to External Customers and Long-Lived Tangible Assets by Geographical Region (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	$ 361,028	$ 259,280
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	235,975	173,269
Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	50,143	25,288
Asia
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	42,657	26,078
Mexico
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	7,647	7,544
S. America
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	24,606	27,101
All foreign countries
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	$ 125,053	$ 86,011

Accounts Receivable and Sales Concentrations - Summary of Accounts Receivables (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Receivables [Abstract]
Trade	$ 135,260	$ 110,165
Less—allowance for doubtful accounts	1,839	1,719	$ 1,069	$ 1,055
Accounts receivable, net	$ 133,421	$ 108,446

Accounts Receivable and Sales Concentrations - Summary of Activity in the Allowance for Doubtful Accounts (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Allowance for Doubtful Accounts Receivable [Roll Forward]
Balance at beginning of year	$ 1,719	$ 1,069	$ 1,055
Additions	754	648	153
Write-offs	(584)	(101)	(59)
Currency impact	(50)	103	(80)
Balance at end of year	$ 1,839	$ 1,719	$ 1,069

Accounts Receivable and Sales Concentrations - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Accounts, Notes, Loans and Financing Receivable [Line Items]
Net sales	$ 199,477	$ 205,683	$ 196,349	$ 169,148	$ 156,135	$ 148,156	$ 157,947	$ 157,555	$ 770,657	$ 619,793	$ 584,954
Bosch
Accounts, Notes, Loans and Financing Receivable [Line Items]
Net sales											$ 59,200
Net Sales \| Customer Concentration Risk \| Bosch
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of consolidated sales											10.00%

Inventories - Summary of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 52,930	$ 37,337
Work in process	42,578	27,669
Finished goods	27,107	17,611
Inventories	$ 122,615	$ 82,617

Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 506,306	$ 371,649
Less—accumulated depreciation	145,278	112,369
Property, plant and equipment, net	361,028	259,280
Land and buildings
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	69,455	54,833
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	401,729	302,470
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 35,122	$ 14,346

Property, Plant and Equipment - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property, plant and equipment acquired	$ 66,000,000	$ 14,000,000
Impairment charges	5,200,000	0	$ 0
Depreciation expense	$ 38,600,000	$ 28,900,000	$ 24,700,000

Goodwill - Changes in Carrying Amount of Goodwill (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Goodwill [Line Items]
Beginning Balance	$ 454,612	$ 443,529
Currency impact		1,631
Goodwill acquired in acquisitions	167,945	9,452
Currency impact and other	(5,705)
Impairments	(182,542)	0	$ 0
Measurement period adjustments	5,142
Ending Balance	439,452	454,612	443,529
Mobile Solutions
Goodwill [Line Items]
Beginning Balance	74,147	73,263
Currency impact		884
Goodwill acquired in acquisitions	0	0
Currency impact and other	(705)
Impairments	(73,442)
Measurement period adjustments	0
Ending Balance	0	74,147	73,263
Power Solutions
Goodwill [Line Items]
Beginning Balance	202,681	201,934
Currency impact		747
Goodwill acquired in acquisitions	2,657	0
Currency impact and other	(1,882)
Impairments	(109,100)
Measurement period adjustments	149
Ending Balance	94,505	202,681	201,934
Life Sciences
Goodwill [Line Items]
Beginning Balance	177,784	168,332
Currency impact		0
Goodwill acquired in acquisitions	165,288	9,452
Currency impact and other	(3,118)
Impairments	0
Measurement period adjustments	4,993
Ending Balance	$ 344,947	$ 177,784	$ 168,332

Goodwill - Changes in Gross Carrying Amount of Goodwill and Accumulated Impairment (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Goodwill [Line Items]
Gross Carrying Amount	$ 624,499	$ 456,412
Accumulated Impairment Charges	(185,047)	(1,800)
Goodwill	439,452	454,612	$ 443,529
Mobile Solutions
Goodwill [Line Items]
Gross Carrying Amount	74,147	74,147
Accumulated Impairment Charges	(74,147)	0
Goodwill	0	74,147	73,263
Power Solutions
Goodwill [Line Items]
Gross Carrying Amount	205,405	204,481
Accumulated Impairment Charges	(110,900)	(1,800)
Goodwill	94,505	202,681	201,934
Life Sciences
Goodwill [Line Items]
Gross Carrying Amount	344,947	177,784
Accumulated Impairment Charges	0	0
Goodwill	$ 344,947	$ 177,784	$ 168,332

Goodwill - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Jun. 30, 2018
Goodwill [Line Items]
Goodwill	$ 439,452	$ 454,612	$ 443,529
Goodwill impairment	182,542	0	0
Intangible assets, net	376,248	237,702	254,263
Gross carrying value	464,571	301,230
Paragon Medical
Goodwill [Line Items]
Goodwill	161,820			$ 157,421
Other
Goodwill [Line Items]
Goodwill	8,000
Southern California Technical Arts, Inc.
Goodwill [Line Items]
Goodwill	2,800
Mobile Solutions
Goodwill [Line Items]
Goodwill	0	74,147	73,263
Goodwill impairment	73,442
Intangible assets, net	35,892	39,446	42,928
Power Solutions
Goodwill [Line Items]
Goodwill	94,505	202,681	201,934
Goodwill impairment	109,100
Intangible assets, net	95,991	105,030	115,928
Reduction in goodwill	1,600
Life Sciences
Goodwill [Line Items]
Goodwill	344,947	177,784	168,332
Goodwill impairment	0
Intangible assets, net	$ 244,365	$ 93,226	$ 95,407
Percentage of fair value in excess of carrying amount	3.70%
Gross carrying value	$ 244,400

Intangible Assets, Net - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2018
Finite-Lived Intangible Assets [Line Items]
Intangible assets	$ 171,113,000	$ 6,900,000
Estimated intangible assets useful life	19 years
Impairment of intangible assets, finite-lived	$ 0	$ 0
Paragon Medical
Finite-Lived Intangible Assets [Line Items]
Intangible assets	163,500,000		$ 164,200,000
Other
Finite-Lived Intangible Assets [Line Items]
Intangible assets	5,700,000
Southern California Technical Arts, Inc.
Finite-Lived Intangible Assets [Line Items]
Intangible assets	$ 1,900,000

Intangible Assets, Net - Estimated Useful Life of Intangible Assets (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018 USD ($)
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value as of Acquisition Date	$ 171,113
Weighted Average Estimated Useful Life in Years	19 years
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value as of Acquisition Date	$ 146,800
Weighted Average Estimated Useful Life in Years	20 years
Trademark and trade name
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value as of Acquisition Date	$ 14,700
Weighted Average Estimated Useful Life in Years	29 years
Other
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value as of Acquisition Date	$ 9,613
Weighted Average Estimated Useful Life in Years	1 year

Intangible Assets, Net - Summary of Carrying Amount of Intangible Assets by Segment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Beginning balance	$ 237,702	$ 254,263
Amortization	(32,553)	(23,460)
Currency impacts	(14)	(1)
Intangible assets subject to amortization	171,113	6,900
Measurement period adjustments	0
Ending balance	376,248	237,702
Mobile Solutions
Finite-Lived Intangible Assets [Line Items]
Beginning balance	39,446	42,928
Amortization	(3,540)	(3,481)
Currency impacts	(14)	(1)
Intangible assets subject to amortization	0	0
Measurement period adjustments	0
Ending balance	35,892	39,446
Power Solutions
Finite-Lived Intangible Assets [Line Items]
Beginning balance	105,030	115,928
Amortization	(10,939)	(10,898)
Currency impacts	0	0
Intangible assets subject to amortization	1,900	0
Measurement period adjustments	0
Ending balance	95,991	105,030
Life Sciences
Finite-Lived Intangible Assets [Line Items]
Beginning balance	93,226	95,407
Amortization	(18,074)	(9,081)
Currency impacts	0	0
Intangible assets subject to amortization	169,213	6,900
Measurement period adjustments	0
Ending balance	$ 244,365	$ 93,226

Intangible Assets, Net - Summary of Carrying Amount of Intangible Assets by Major Asset Class (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life in Years	19 years
Gross Carrying Value as of Acquisition Date	$ 464,571	$ 301,230
Accumulated Amortization	(88,323)	(63,528)
Intangible assets, net	376,248	237,702	$ 254,263
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value as of Acquisition Date	428,830	282,030
Accumulated Amortization	(75,581)	(52,408)
Intangible assets, net	353,249	229,622
Trademark and trade name
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value as of Acquisition Date	25,100	10,460
Accumulated Amortization	(4,085)	(2,703)
Intangible assets, net	21,015	7,757
Other
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value as of Acquisition Date	10,641	8,740
Accumulated Amortization	(8,657)	(8,417)
Intangible assets, net	$ 1,984	$ 323
Minimum \| Customer relationships
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life in Years	12 years
Minimum \| Trademark and trade name
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life in Years	8 years
Minimum \| Other
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life in Years	1 year
Maximum \| Customer relationships
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life in Years	20 years
Maximum \| Trademark and trade name
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life in Years	30 years
Maximum \| Other
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life in Years	5 years

Intangible Assets, Net - Schedule of Finite Lived Intangible Assets Future Amortization Expense Table (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
2019	$ 47,009
2020	45,357
2021	41,415
2022	38,464
2023	36,625
Thereafter	167,378
Intangible assets, net	$ 376,248	$ 237,702	$ 254,263

Investment in Joint Venture - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Schedule of Equity Method Investments [Line Items]
Impairment charge									$ 16,589
Net sales	$ 199,477	$ 205,683	$ 196,349	$ 169,148	$ 156,135	$ 148,156	$ 157,947	$ 157,555	$ 770,657	$ 619,793	$ 584,954
Joint Venture
Schedule of Equity Method Investments [Line Items]
Investment in joint venture	49.00%								49.00%
Net sales									$ 300	200	100
Amount due from joint venture	$ 100				$ 100				$ 100	$ 100	$ 100
Wuxi Weifu Autocam Precision Machinery Company, Ltd.
Schedule of Equity Method Investments [Line Items]
Investment in joint venture	49.00%								49.00%

Investment in Joint Venture - Summarized Activity Related to Investment in Joint Venture (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Schedule of Equity Method Investments [Line Items]
Beginning Balance	$ 39,822
Share of earnings	(14,390)	$ 5,211	$ 5,938
Impairment	(16,589)
Ending Balance	20,364	39,822
Joint Venture
Schedule of Equity Method Investments [Line Items]
Beginning Balance	39,822
Share of earnings	2,543
Dividends declared and paid by joint venture	(2,842)
Accretion of basis difference from purchase accounting	(343)
Balance as of December 31, 2018	(2,227)
Ending Balance	$ 20,364	$ 39,822

Investment in Joint Venture - Summarized Income Statement Information of Unconsolidated Joint Venture (Detail) - Joint Venture - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Schedule of Equity Method Investments [Line Items]
Net sales	$ 69,901	$ 74,805	$ 65,756
Cost of sales	57,596	57,514	44,530
Income from operations	6,853	13,659	16,268
Net income	$ 4,646	$ 11,442	$ 13,702

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Taxes [Line Items]
Federal corporate income tax rate		21.00%	35.00%	34.00%
Net tax benefit			$ 51,800,000
Effective tax rate on non deductible expense		4.20%	134.20%	50.00%
Deferred tax asset valuation allowance change in amount net		$ 6,900,000	$ 3,500,000	$ 1,700,000
Deferred tax asset valuation allowance amount decrease				(200,000)
Unrecognized tax benefits		4,609,000	5,655,000	4,741,000	$ 5,724,000
Amount of unrecognized tax benefits would, if recognized, impact effective tax rate		4,000,000
Decrease in unrecognized income benefits and interest		1,800,000
Impact of these tax holidays decreased foreign taxes		0	$ 800,000	$ 700,000
Benefit of the tax holidays on net income per share (diluted)			$ 0.03	$ 0.03
State Net Operating Loss Carryforwards
Income Taxes [Line Items]
Deferred tax asset valuation allowance amount increase			$ 2,300,000	$ 1,900,000
Foreign Net Operating Loss Carryforwards
Income Taxes [Line Items]
Deferred tax asset valuation allowance amount increase			1,200,000
Foreign Tax Authority
Income Taxes [Line Items]
Interest on income taxes accrued		100,000		100,000
NOL carryovers		$ 10,700,000
NOL carryovers expiration beginning year		2026
Tax credits in foreign jurisdictions		$ 4,100,000
United States
Income Taxes [Line Items]
Interest on income taxes accrued		$ 200,000	200,000	$ 200,000
NOL carryovers expiration beginning year		2024
Tax credits in foreign jurisdictions		$ 5,300,000
State and Local Jurisdiction
Income Taxes [Line Items]
NOL carryovers		$ 101,600,000
NOL carryovers expiration beginning year		2030
Scenario, Adjustment
Income Taxes [Line Items]
Net tax benefit			$ 800,000
Scenario, Forecast
Income Taxes [Line Items]
Net tax benefit	$ 6,000,000

Income Taxes - Loss from Continuing Operations Before Benefit for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Loss from continuing operations before benefit for income taxes and share of net income from joint venture
United States	$ (263,499)	$ (71,603)	$ (39,160)
Foreign	2,465	12,730	8,294
Loss from continuing operations before benefit for income taxes and share of net income from joint venture	$ (261,034)	$ (58,873)	$ (30,866)

Income Taxes - Income Tax Benefit (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Current taxes:
U.S. Federal	$ 8,150	$ (47,916)	$ (2,595)
State	584	(12,226)	679
Foreign	3,086	4,310	2,004
Total current tax expense (benefit)	11,820	(55,832)	88
Deferred taxes:
U.S. Federal	(16,129)	(25,017)	(9,679)
State	(780)	3,009	(6,406)
Deferred tax valuation allowance	(3,565)	710	1,882
Foreign	(2,303)	(1,896)	(1,323)
Total deferred tax benefit	(22,777)	(23,194)	(15,526)
Total income tax benefit	$ (10,957)	$ (79,026)	$ (15,438)

Income Taxes - Reconciliation of Income Taxes Based on U.S. Federal Statutory Rate (Detail)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
U.S federal statutory income tax rate	21.00%	35.00%	34.00%
Change in valuation allowance	(0.90%)	(1.20%)	(6.10%)
Foreign tax credits, exclusive of tax reform	(0.00%)	(13.80%)	8.20%
State taxes, net of federal taxes, exclusive of tax reform	0.40%	9.10%	5.70%
Non-U.S. earnings taxed at different rates	1.20%	1.70%	4.80%
Non-deductible mergers and acquisitions costs	(0.20%)	0.00%	0.00%
GILTI	(0.30%)	0.00%	0.00%
Goodwill impairment	(15.50%)	0.00%	0.00%
R&D Tax credit	0.30%	0.30%	0.90%
Change in uncertain tax positions	0.30%	(0.40%)	3.20%
Impact of Tax Reform
Toll Charge, net of foreign tax credit	0.60%	(11.50%)	0.00%
Remeasurement of deferred taxes pursuant to tax reform	(0.90%)	65.60%	0.00%
Tax Reform impact on divestiture of business segment	0.00%	33.90%	0.00%
Section 199/Domestic Production Deduction	(0.00%)	0.80%	(0.00%)
Divestiture of Business Segment, exclusive of tax reform	(0.90%)	13.60%	0.00%
Return to provision	(0.80%)	0.00%	0.00%
Prior period revisions	0.00%	0.50%	4.20%
Foreign JV net income	0.00%	0.00%	(4.10%)
Other adjustments, net	(0.10%)	0.60%	(0.80%)
Effective tax rate	4.20%	134.20%	50.00%

Income Taxes - Principal Components of Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Deferred income tax liabilities:
Tax in excess of book depreciation	$ 37,425	$ 34,143
Goodwill	0	58
Intangible assets	80,623	50,688
Other deferred tax liabilities	794	389
Total deferred income tax liabilities	118,842	85,278
Deferred income tax assets:
Interest expense limitation	9,968	0
Goodwill	1,441	2,067
Inventories	2,745	2,248
Pension/Personnel accruals	1,317	1,596
Net operating loss carry forwards	9,321	6,950
Foreign tax credits	5,345	0
Credit carry forwards	4,130	3,427
Accruals and reserves	1,531	2,015
Other deferred tax assets	4,022	3,019
Deferred income tax assets before Valuation Allowance	39,820	21,322
Valuation allowance on deferred tax assets	(14,460)	(7,608)	$ (4,090)	$ (2,376)
Total deferred income tax assets	25,360	13,714
Net deferred income tax liabilities	$ 93,482	$ 71,564

Income Taxes - Summary of Activity in Total Valuation Allowances (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of year	$ 7,608	$ 4,090	$ 2,376
Additions	6,852	3,518	1,882
Recoveries	0	0	(168)
Balance at end of year	$ 14,460	$ 7,608	$ 4,090

Income Taxes - Summary of Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits, Excluding Interest and Penalties (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at beginning of year	$ 5,655	$ 4,741	$ 5,724
Additions for tax positions of prior years	304	1,404	179
Reductions for tax positions of prior years	(1,350)	(490)	(1,162)
Balance at end of year	$ 4,609	$ 5,655	$ 4,741

Debt - Summary of Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Total	$ 859,593	$ 828,565
Principal, net of current portion	828,313	811,282
Less current maturities of long-term debt	31,280	17,283
Less unamortized debt issuance costs	16,842	20,477
Long-term debt, net of current portion	811,471	790,805
Senior Secured Term Loan B
Debt Instrument [Line Items]
Senior debt	532,063	534,250
Incremental Term Loan
Debt Instrument [Line Items]
Senior debt	279,000	291,000
Senior Secured Revolving Facility
Debt Instrument [Line Items]
Line of credit	38,720	0
Foreign Line of Credit
Debt Instrument [Line Items]
International lines of credit and other loans	9,810	$ 3,315
Less current maturities of long-term debt	$ 6,800

Debt - Additional Information (Detail) - USD ($)						1 Months Ended	12 Months Ended
Debt - Additional Information (Detail) - USD ($)	Dec. 26, 2018	Sep. 18, 2018	May 07, 2018	Nov. 24, 2017	Nov. 23, 2017	Apr. 30, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 25, 2018
Line of Credit Facility [Line Items]
Capitalized interest costs							$ 1,200,000	$ 1,100,000	$ 1,600,000
Unamortized debt issuance expense							16,842,000	20,477,000
Cash paid for call premium						$ 31,600,000
Loss on extinguishment of debt and write-off of debt issuance costs							19,562,000	42,087,000	$ 2,589,000
Current maturities of long-term debt							31,280,000	17,283,000
Incremental Term Loan
Line of Credit Facility [Line Items]
Debt instrument face amount							$ 300,000,000
Interest rate during period				5.75%
Incremental Term Loan \| London Interbank Offered Rate (LIBOR)
Line of Credit Facility [Line Items]
Decrease in basis spread on variable rate					0.50%
Basis spread on variable rate				3.25%	3.75%
Second Lien Credit Agreement
Line of Credit Facility [Line Items]
Debt instrument face amount		$ 200,000,000	$ 200,000,000
Payments of debt issuance costs			16,700,000
Prepayment penalty percentage		2.00%
Cash paid for call premium		$ 4,000,000
Loss on extinguishment of debt and write-off of debt issuance costs		$ 2,600,000	$ 12,900,000
Second Lien Credit Agreement \| London Interbank Offered Rate (LIBOR)
Line of Credit Facility [Line Items]
Basis spread on variable rate			8.00%
Second Lien Credit Agreement \| London Interbank Offered Rate (LIBOR) \| Minimum
Line of Credit Facility [Line Items]
Basis for variable rate			1.00%
Second Lien Credit Agreement \| Base Rate
Line of Credit Facility [Line Items]
Basis for variable rate			7.00%
Revolving Credit Facility
Line of Credit Facility [Line Items]
Unamortized debt issuance expense			$ 3,800,000
Senior Secured Revolving Facility
Line of Credit Facility [Line Items]
Line of credit face amount	$ 143,000,000
Interest rate during period							6.00%
Payments of debt issuance costs	100,000
Commitment fee percentage							0.50%
Available borrowing capacity	$ 125,000,000						$ 125,000,000			$ 100,000,000
Line of credit							38,720,000	0
Senior Secured Revolving Facility \| London Interbank Offered Rate (LIBOR)
Line of Credit Facility [Line Items]
Basis spread on variable rate	3.50%
Senior Secured Term Loan B
Line of Credit Facility [Line Items]
Debt instrument face amount							$ 545,000,000
Interest rate during period							6.25%
Senior Secured Term Loan B \| London Interbank Offered Rate (LIBOR)
Line of Credit Facility [Line Items]
Decrease in basis spread on variable rate					0.50%
Basis spread on variable rate				3.75%	4.25%
Senior Secured Term Loan B \| London Interbank Offered Rate (LIBOR) \| Minimum
Line of Credit Facility [Line Items]
Interest rate				0.75%
Foreign Line of Credit
Line of Credit Facility [Line Items]
French safeguard obligations							$ 9,810,000	$ 3,315,000
Current maturities of long-term debt							$ 6,800,000

Debt - Aggregate Maturities of Long-Term Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Debt Disclosure [Abstract]
2019	$ 31,280
2020	50,097
2021	261,094
2022	515,157
2023	344
Thereafter	1,621
Total	$ 859,593	$ 828,565

Restructuring and Integration - Summary of Restructuring and Integration Charges and Reserve Activity (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Restructuring Cost and Reserve [Line Items]
Severance and other costs	$ 2,064	$ 17	$ 1,687
Site closure and other associated costs	63	369	3,971
Restructuring Reserve [Roll Forward]
Reserve beginning balance	1,099	2,625	2,732
Charges	2,127	386	5,658
Non-cash Adjustments	(56)	(164)	(2,420)
Cash Reductions	(2,024)	(1,748)	(3,345)
Reserve ending balance	1,146	1,099	2,625
Severance and Other Employee Costs
Restructuring Reserve [Roll Forward]
Reserve beginning balance	0	1,000	887
Charges	2,064	17	1,687
Non-cash Adjustments	0	(164)	(278)
Cash Reductions	(942)	(853)	(1,296)
Reserve ending balance	1,122	0	1,000
Site Closure Costs
Restructuring Reserve [Roll Forward]
Reserve beginning balance	1,099	1,625	1,845
Charges	63	369	3,971
Non-cash Adjustments	(56)	0	(2,142)
Cash Reductions	(1,082)	(895)	(2,049)
Reserve ending balance	24	1,099	1,625
Operating Segments \| Mobile Solutions
Restructuring Cost and Reserve [Line Items]
Severance and other costs	0	17	851
Site closure and other associated costs	63	369	3,488
Restructuring Reserve [Roll Forward]
Charges	63	386	4,339
Operating Segments \| Mobile Solutions \| Severance and Other Employee Costs
Restructuring Reserve [Roll Forward]
Charges			800
Operating Segments \| Mobile Solutions \| Site Closure Costs
Restructuring Reserve [Roll Forward]
Charges			3,500
Operating Segments \| Power Solutions
Restructuring Cost and Reserve [Line Items]
Severance and other costs	0	0	455
Site closure and other associated costs	0	0	263
Restructuring Reserve [Roll Forward]
Charges	0	0	718
Operating Segments \| Life Sciences
Restructuring Cost and Reserve [Line Items]
Severance and other costs	1,336	0	381
Site closure and other associated costs	0	0	220
Restructuring Reserve [Roll Forward]
Charges	1,336	0	601
Corporate And Eliminations
Restructuring Cost and Reserve [Line Items]
Severance and other costs	728	0	0
Site closure and other associated costs	0	0	0
Restructuring Reserve [Roll Forward]
Charges	$ 728	$ 0	$ 0

Restructuring and Integration - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Restructuring Cost and Reserve [Line Items]
Severance and other costs	$ 2,064	$ 17	$ 1,687
Restructuring and integration expense, net	2,127	386	5,658
Severance and restructuring cost	$ 2,127	386	5,658
Pay period for accrued restructuring and integration costs	2 years 2 months 25 days
Expected cost remaining	$ 700
Severance and Other Employee Costs
Restructuring Cost and Reserve [Line Items]
Severance and restructuring cost	2,064	17	1,687
Site Closure Costs
Restructuring Cost and Reserve [Line Items]
Severance and restructuring cost	63	369	3,971
Corporate And Eliminations
Restructuring Cost and Reserve [Line Items]
Severance and other costs	728	0	0
Severance and restructuring cost	728	0	0
Operating Segments \| Mobile Solutions
Restructuring Cost and Reserve [Line Items]
Severance and other costs	0	17	851
Restructuring and integration expense, net		400	4,300
Severance and restructuring cost	63	386	4,339
Operating Segments \| Mobile Solutions \| Severance and Other Employee Costs
Restructuring Cost and Reserve [Line Items]
Severance and restructuring cost			800
Operating Segments \| Mobile Solutions \| Site Closure Costs
Restructuring Cost and Reserve [Line Items]
Severance and restructuring cost			3,500
Operating Segments \| Power Solutions
Restructuring Cost and Reserve [Line Items]
Severance and other costs	0	0	455
Severance and restructuring cost	0	0	718
Operating Segments \| Life Sciences
Restructuring Cost and Reserve [Line Items]
Severance and other costs	1,336	0	381
Severance and restructuring cost	$ 1,336	$ 0	$ 601

Commitments and Contingencies - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Contingencies And Commitments [Line Items]
Rent expenses	$ 12,400,000	$ 7,600,000	$ 7,200,000
Amount accrued for estimation of loss	0
Minimum
Contingencies And Commitments [Line Items]
Possible loss estimated	0
Maximum
Contingencies And Commitments [Line Items]
Possible loss estimated	$ 6,000,000

Commitments and Contingencies - Schedule by Year of Future Minimum Lease Payments (Detail) $ in Thousands	Dec. 31, 2018 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2019	$ 13,337
2020	11,515
2021	10,557
2022	10,293
2023	8,752
Thereafter	53,945
Total minimum payments	$ 108,399

Equity Offering - Additional Information (Detail) $ / shares in Units, shares in Millions, $ in Millions	Sep. 18, 2018 USD ($) $ / shares shares
Equity Offering [Abstract]
Number of shares of common stock sold (in shares) \| shares	14.4
Public offering price per share \| $ / shares	$ 16.00
Net proceeds to NN from the offering \| $	$ 217.3

Revenue from Contracts with Customers Contract Liabilities from Contract with Customer (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenue from Contract with Customer [Abstract]
Deferred revenue	$ 2,974	$ 2,124
Deferred revenue recognized	$ 1,900

Revenue from Contracts with Customers Financial Statement Impact of Adopting ASC 606 (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Net sales	$ 199,477	$ 205,683	$ 196,349	$ 169,148	$ 156,135	$ 148,156	$ 157,947	$ 157,555	$ 770,657	$ 619,793	$ 584,954
Cost of sales									588,205
Income (loss) from operations									(178,888)	33,114	$ 34,779
Accounts receivable, net	133,421								133,421
Inventories	122,615				$ 82,617				122,615	$ 82,617
Calculated under Revenue Guidance in Effect before Topic 606
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Net sales									770,654
Cost of sales									588,202
Income (loss) from operations									(178,888)
Accounts receivable, net	132,810								132,810
Inventories	122,988								122,988
Difference between Revenue Guidance in Effect before and after Topic 606 \| Accounting Standards Update 2014-09
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Net sales									3
Cost of sales									3
Income (loss) from operations									0
Accounts receivable, net	611								611
Inventories	$ (373)								$ (373)

Share-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares authorized to issued as options (in shares)	1,900,000
Share-based compensation expense	$ 2,416	$ 5,496	$ 3,935
Decrease in share-based compensation expense from change in vesting	(2,000)
Tax benefit for share-based compensation cost	700	$ 1,600	$ 600
Unrecognized compensation costs related to unvested awards	$ 4,000
Unrecognized compensation costs, period for recognition	1 year 10 months 6 days
Term life of options	10 years
Stock awards granted vesting period		3 years	3 years
Number of options granted	57,800	125,700	167,000
Weighted average grant date fair value of the options granted	$ 10.60	$ 11.84	$ 5.02
Cash proceeds from the exercise of options	$ 300	$ 3,100	$ 2,800
Tax benefit recognized from stock option exercises	100	200	100
Total intrinsic value of options exercised	$ 477	3,800	2,900
Selling, General and Administrative Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense		$ 1,000	$ 500
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock awards granted vesting period	3 years
Stock units issued (in shares)	86,516	85,393	152,510
Fair value assumptions, exercise price (in dollars per share)	$ 24.55	$ 24.29	$ 11.39
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	$ 1,800	$ 2,100	$ 2,600
TSR Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock units issued (in shares)	55,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value		$ 1,200
Percentage of shares issuable based on threshold performance	50.00%
Percentage of shares issuable based on target performance	100.00%
Percentage of shares issuable based on maximum performance	150.00%
Threshold performance, percentage	35.00%	35.00%	35.00%
ROIC Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Decrease in share-based compensation expense from change in vesting	$ (800)	$ (400)
Stock units issued (in shares)	55,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value		$ 900
Options awards vested	0
Percentage of shares issuable based on threshold performance	35.00%
Percentage of shares issuable based on target performance	100.00%
Percentage of shares issuable based on maximum performance	150.00%
Threshold performance, percentage	15.50%	15.00%	15.50%
Officers and Key Employees \| Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock awards granted vesting period	3 years
Non-executive Directors \| Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock awards granted vesting period	1 year	1 year	1 year
Adjustment \| ROIC Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividends accrued for performance share units	$ 100

Share-Based Compensation - Components of Share-Based Compensation Expense by Type of Award (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ 2,416	$ 5,496	$ 3,935
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	678	1,078	687
Restricted stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	1,630	1,968	2,061
Performance share units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	2,076	2,450	1,187
Change in Estimate of Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ (1,968)	$ 0	$ 0

Share-Based Compensation - Weighted Average Assumptions Relevant to Determining the Fair Value at the Dates of Grant and Stock Option Modification (Detail) - Stock options	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	6 years	6 years	6 years
Average risk-free interest rate	2.66%	2.03%	1.43%
Expected dividend yield	1.15%	1.16%	2.48%
Expected volatility	47.69%	56.56%	59.23%
Expected forfeiture rate	4.00%	3.00%	3.00%

Share-Based Compensation - Reconciliation of Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Beginning balance (in shares)	746,000
Granted (in shares)	57,800	125,700	167,000
Exercised (in shares)	(27,000)
Forfeited (in shares)	(6,000)
Ending balance (in shares)	771,000	746,000
Exercisable (in shares)	625,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Beginning balance (in usd per share)	$ 14.33
Granted (in usd per share)	24.47
Exercised (in usd per share)	10.15
Forfeited (in usd per share)	22.39
Ending balance (in usd per share)	15.17	$ 14.33
Exercisable (in usd per share)	$ 13.63
Weighted-Average Remaining Contractual Term, Outstanding	5 years 7 months 12 days
Weighted- Average Remaining Contractual Term, Options exercisable	4 years 10 months 12 days
Aggregate Intrinsic Value, Exercised	$ 477	$ 3,800	$ 2,900
Aggregate Intrinsic Value, Outstanding	0
Aggregate Intrinsic Value, Options exercisable	$ 0

Share-Based Compensation - Reconciliation of Restricted Stock Option Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance (in shares)	152,000
Granted (in shares)	86,516	85,393	152,510
Vested (in shares)	(93,000)
Forfeited (in shares)	0
Ending balance (in shares)	146,000	152,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Beginning balance (in usd per share)	$ 19.21
Granted (in usd per share)	24.55
Vested (in usd per share)	19.69
Forfeited (in usd per share)	0.00
Ending balance (in usd per share)	$ 22.07	$ 19.21
TSR Awards
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance (in shares)	130,000
Granted (in shares)	55,000
Vested (in shares)	0
Expired (in shares)	(78,000)
Forfeited (in shares)	(13,000)
Ending balance (in shares)	94,000	130,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Beginning balance (in usd per share)	$ 16.60
Granted (in usd per share)	24.65
Vested (in usd per share)	$ 0.00
Expired (in usd per share)	9.38
Forfeited (in usd per share)	$ 14.50
Ending balance (in usd per share)	$ 26.84	$ 16.60
ROIC Awards
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance (in shares)	136,000
Granted (in shares)	55,000
Vested (in shares)	0
Expired (in shares)	(77,000)
Forfeited (in shares)	(14,000)
Ending balance (in shares)	100,000	136,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Beginning balance (in usd per share)	$ 16.27
Granted (in usd per share)	24.55
Vested (in usd per share)	$ 0.00
Expired (in usd per share)	11.31
Forfeited (in usd per share)	$ 14.86
Ending balance (in usd per share)	$ 24.39	$ 16.27

Share-Based Compensation - Schedule of Performance Based Awards Goals with Respect to TSR and ROIC (Detail)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
ROIC Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Threshold Performance of Shares, percentage	35.00%
Target Performance of Shares, percentage	100.00%
Maximum Performance of Shares, percentage	150.00%
Threshold performance, percentage	15.50%	15.00%	15.50%
Target Performance, percentage	18.00%	17.50%	18.00%
Maximum Performance, percentage	19.50%	20.00%	20.50%
TSR Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Threshold Performance of Shares, percentage	50.00%
Target Performance of Shares, percentage	100.00%
Maximum Performance of Shares, percentage	150.00%
Threshold performance, percentage	35.00%	35.00%	35.00%
Target Performance, percentage	50.00%	50.00%	50.00%
Maximum Performance, percentage	75.00%	75.00%	75.00%

Share-Based Compensation - Summary of Number of Awards Granted and Grand Date Fair Value (Detail) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Deferred Tax Assets Valuation Allowance [Line Items]
Grant date fair value	$ 24.47
TSR Awards
Deferred Tax Assets Valuation Allowance [Line Items]
Number of shares (in shares)	55	46	101
Grant date fair value	$ 24.65	$ 29.84	$ 9.38
ROIC Awards
Deferred Tax Assets Valuation Allowance [Line Items]
Number of shares (in shares)	55	53	101
Grant date fair value	$ 24.55	$ 24.20	$ 11.31

Accumulated Other Comprehensive Income - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Equity [Abstract]
Foreign currency translation gain (loss)	$ (13,880)	$ 22,094	$ (10,623)
Reclassification adjustment for discontinued operations		(9,200)
Change in fair value of interest rate swap	$ 0	$ 0	$ 1,910

Net Income (Loss) Per Share - Summary of Net Income (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Earnings Per Share [Abstract]
Income (loss) from continuing operations	$ (220,189)	$ (13,784)	$ (24,511)	$ (5,983)	$ 53,325	$ (3,480)	$ (26,374)	$ 1,893	$ (264,467)	$ 25,364	$ (9,490)
Income from discontinued operations, net of tax					$ (2,507)	$ 129,441	$ 5,236	$ 5,518	0	137,688	16,153
Net income (loss)									$ (264,467)	$ 163,052	$ 6,663
Weighted average shares outstanding (in shares)									31,678	27,433	27,016
Effect of dilutive stock options (in shares)									0	322	0
Weighted average shares outstanding (in shares)									31,678	27,755	27,016
Basic income (loss) from continuing operations per share (in usd per share)	$ (5.25)	$ (0.48)	$ (0.89)	$ (0.22)	$ 1.93	$ (0.13)	$ (0.96)	$ 0.07	$ (8.35)	$ 0.92	$ (0.35)
Basic income from discontinued operations per share (in shares)									0.00	5.02	0.60
Basic net income (loss) per share (in usd per share)	(5.25)	(0.48)	(0.89)	(0.22)	1.84	4.57	(0.77)	0.27	(8.35)	5.94	0.25
Diluted income (loss) from continuing operations per share (in usd per share)	(5.25)	(0.48)	(0.89)	(0.22)	1.91	(0.13)	(0.96)	0.07	(8.35)	0.91	(0.35)
Diluted income from discontinued operations per share (in usd per share)									0.00	4.96	0.60
Diluted net income (loss) per share (in usd per share)	$ (5.25)	$ (0.48)	$ (0.89)	$ (0.22)	$ 1.82	$ 4.57	$ (0.77)	$ 0.27	(8.35)	5.87	0.25
Cash dividends per common share (in usd per share)									$ 0.28	$ 0.28	$ 0.28

Net Income (Loss) Per Share - Additional Information (Detail) - $ / shares shares in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Net Income Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share minimum price range	$ 4.42	$ 4.42	$ 4.42
Anti-dilutive securities excluded from computation of earnings per share maximum price range one	$ 25.16	$ 25.16	$ 25.16
Stock options
Net Income Per Share [Line Items]
Anti-dilutive securities excluded from the calculation of diluted earnings per share from continuing operation	0.4	0.4	0.8

Fair Value Measurements - Additional Information (Detail)	Dec. 31, 2018 USD ($)
Fair Value Disclosures [Abstract]
Fair value of fixed-rate debt	$ 0
Interest rate swaps outstanding	$ 0

Quarterly Results of Operations (Unaudited) - Summary of Unaudited Quarterly Results of Operations (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Net sales	$ 199,477	$ 205,683	$ 196,349	$ 169,148	$ 156,135	$ 148,156	$ 157,947	$ 157,555	$ 770,657	$ 619,793	$ 584,954
Cost of sales (exclusive of depreciation and amortization)	156,713	156,408	148,640	126,444	118,814	111,272	114,514	114,480	588,205	459,080	428,843
Income (loss) from continuing operations	(220,189)	(13,784)	(24,511)	(5,983)	53,325	(3,480)	(26,374)	1,893	(264,467)	25,364	(9,490)
Income from discontinued operations, net of tax					(2,507)	129,441	5,236	5,518	0	137,688	16,153
Net income (loss)	(220,189)	(13,784)	(24,511)	(5,983)	50,818	125,961	(21,138)	7,411
Comprehensive income (loss)	$ (219,560)	$ (17,977)	$ (40,292)	$ (518)	$ 51,885	$ 123,129	$ (11,627)	$ 12,516	$ (278,347)	$ 175,903	$ (2,050)
Basic income (loss) from continuing operations per share (in usd per share)	$ (5.25)	$ (0.48)	$ (0.89)	$ (0.22)	$ 1.93	$ (0.13)	$ (0.96)	$ 0.07	$ (8.35)	$ 0.92	$ (0.35)
Basic net income (loss) per share (in usd per share)	(5.25)	(0.48)	(0.89)	(0.22)	1.84	4.57	(0.77)	0.27	(8.35)	5.94	0.25
Diluted income (loss) from continuing operations per share (in usd per share)	(5.25)	(0.48)	(0.89)	(0.22)	1.91	(0.13)	(0.96)	0.07	(8.35)	0.91	(0.35)
Diluted net income (loss) per share (in usd per share)	$ (5.25)	$ (0.48)	$ (0.89)	$ (0.22)	$ 1.82	$ 4.57	$ (0.77)	$ 0.27	$ (8.35)	$ 5.87	$ 0.25

Subsequent Event - Narrative (Details)	Feb. 08, 2019 USD ($)
Interest Rate Swap \| Subsequent Event
Subsequent Event [Line Items]
Notional amount	$ 700,000,000

Subsequent Events - Additional Information (Detail)	Feb. 22, 2018
Other
Subsequent Event [Line Items]
Acquisition percentage	100.00%

Label	Element	Value
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents	us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	$ 3,700,000